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ABSTRACT
An Analysis of Situated Meaning in Direet-To-Consnmer
Pharmaeentieal Advertising
by
Susan E. Garcia
Dr. Denise Tillery, Examination Committee Chair
Associate Professor o f English
University o f Nevada, Las Vegas
This thesis uses interpretive discourse analysis to critically examine the situated
meaning o f prescription drug Direct-To-Consumer Advertising (DTCA) as compared to
the situated meaning o f historical patent DTCA. Specifically, I apply James Paul Gee’s
theory o f analysis to show how the DTCA, past and present, builds identity, connections,
and sign systems and knowledge. My analysis demonstrates that the coverage and
convergence o f these building tasks in both prescription and patent DTCA indicate that
today’s pharmaceutical companies’ situated meaning is not significantly different from
the patent medicine advertising o f the past. Despite pharmaceutical companies’ claims
that the prescription DTCA educates consumers, the discourse does not substantiate a
situated meaning beyond that o f a manufacturer selling a product. Understanding the
motivation and language o f pharmaceutical advertising will enable us, as consumers and
patients, to make sound decisions about the medications we endorse.

Ill

TABLE OF CONTENTS
ABSTRACT..................................................................................................................................iii
LIST OF FIG U R ES...................................................................................................................... v
ACKNOW LEDGM ENTS.....................

vi

CHAPTER 1 INTRODUCTION................................................................................................1
Background to this DTCA Study............................................................................................ 2
Review o f Literature on Patent and Prescription Drug Advertising.................................. 7
M ethodology............................................................................................................................ 17
CHAPTER 2 BUILDING ID ENTITIES................................................................................20
CHAPTER 3 BUILDING CONNECTIONS......................................................................... 40
CHAPTER 4 SIGN SYSTEMS AND KNOWLEDGE........................................................ 62
CHAPTER 5 MAKING A VALID CONCLUSION............................................................ 86
REFEREN CES.......................................................................................................................... 104
V IT A ........................................................................................................................................... no

IV

LIST OF FIGURES
Figure I . Timeline for Regulation o f Drugs and D TCA ........................................................5
Figure 2. Top o f Advertisement for Lydia Pinkham’s Vegetable Compound - 1881.... 25
Figure 3. Top Portions o f Advertisement for Peruna - 1899 (left) and 1901 (right)

27

Figure 4. Top Portion o f Advertisement for Peruna - 18 8 6 ...............................................28
Figure 5. Top Portion o f Advertisement for Nexium - 2 0 0 6 .............................................32
Figure 6. Top Portion o f Advertisement for Lipitor - 2 0 0 7 ............................................... 33
Figure 7. Advertisement for Lydia Pinkham’s Vegetable Compound - 1 9 0 6 ................ 43
Figure 8. Advertisement for Peruna (aka Pe-ru-na) —January 1899.................................47
Figure 9. Bottom Portion o f Advertisement for Nexium - 2007....................................... 53
Figure 10. Reverse Side o f Advertisement for Nexium - Sep 2006.....

57

Figure 11. Reverse Side o f Advertisement for Lipitor - Dec 2007..................................... 59
Figure 12. Advertisement for Lydia Pinkham’s Vegetable Compound - 1879.................68
Figure 13. Advertisement for Peruna - 1901.......................................................................... 69
Figure 14. Advertisement for Lipitor - Dec 2007 ..................................................................74
Figure 15. Advertisement for Nexium - Jul 2 0 0 6 ..................................................................76
Figure 16. Advertisement for Lipitor - Nov 2007..................................................................78
Figure 17. Advertisement for Lydia Pinkham’s Vegetable Compound and advertisement
for Nexium ..............................................................................................................103

ACKNOWLEDGMENTS
The eompletion o f this thesis would not have been possible without the guidanee and
support o f my graduate eommittee. My thesis advisor and committee ehair, Dr. Denise
Tillery, provided me with invaluable assistance on the strueture and content o f my study.
She consistently eneouraged my efforts and cheered me on during the writing proeess. In
addition, my other committee members, Dr. Jeffrey Jablonski, Dr. Timothy Erwin, and
Dr. MaryKay Orgill were equally instrumental in furthering my seholarly approaeh to my
topie and offering their assistanee with any eoneem I might have.
Another UNLV faculty member. Dr. Ed Nagelhout, while not on m y eommittee, was
a key participant in my graduate study. Dr. Nagelhout not only introduced me to James
Paul Gee’s theory of diseourse analysis but also went out o f his way to mentor me in my
role as graduate student and instruetor.
Finally, 1 want to express my gratitude to Patriek, my ineredible husband o f 20 years,
for his unwavering love and support. His patienee and understanding enabled me to
devote m yself to my studies without any doubt about the strength o f our friendship and
marriage.

VI

CHAPTER 1

INTRODUCTION
Consumers are bombarded on a daily basis with advertisements in television
commercials and the printed pages o f popular magazines. As one o f the highest grossing
products sold today, prescription drugs are featured in Direct-To-Consumer Advertising
(DTCA) and have taken their place among ads which offer consumers a choice in what
they purchase. The dilemma o f DTCA for the medical profession, however, lies in the
fact that the consumer cannot simply go out and buy the advertised drugs as they would
any other item featured in an ad - a physician must be involved in the process. As a
result, the medical profession finds itself not only prescribing proper treatments for
patients, but also dissuading patients’ desires for advertised drugs which are not
medically indicated.
This situation is not completely new, and the discourse o f DTCA has long been a
complex factor in a patient’s decision between appropriate and inappropriate healthcare
choices. In fact, opposing viewpoints - typically physicians against pharmaceutical
companies - about the discursive nature o f DTCA complicate a patient’s decision
because opponents of the practice contend it is merely a slick marketing tool which has
not changed since patent medicine days while proponents o f DTCA argue that the
practice is more than simply a product-sales technique and has a much more valuable

intent. As consumers, then, we are left to mediate between the two sides, so we must be
aware o f the authorial intention behind pharmaceutical advertising in order to make
sound healthcare decisions. To that end, using qualitative discourse analysis, this thesis
examines a corpus o f both historical and modem pharmaceutical print advertising to
discover the similarities or differences in situated meaning evident in the persistent
methods o f medicine marketing. Since pharmaceutical advertising is such a large field
for analysis, this study limits its selection o f artifacts to two major patent medicines Lydia Pinkham’s Vegetable Compound and Peruna - from the past and two hugely
popular prescription medications - Nexium and Lipitor - featured in print media today.
This first chapter will establish the background for the study and provide an overview o f
the literature already available on DTCA o f past and present, while foregrounding
society’s vested interest in the tactics o f medicine promotion.

Background to this DTCA Study
A short review o f medication and drug advertising reform as it developed within FDA
regulation is necessary because it provides a historical and sociological context for
looking at the various ways in which medicines were introduced to the public. The topic
o f pharmaceutical advertising is closely tied to events in the development and sale of
drugs and strongly influences society’s views o f these medicines.
Although not officially given the term Direct-To-Consumer Advertising in the
centuries before Food and Drug Administration (FDA) regulation was established, the
medicines offered to the public in earlier centuries via handbills and advertising media set
the precedent for today’s frequently critiqued marketing techniques. In the past.

however, drawing a definitive line between benefieial medieines and fake, or quaek,
nostrums was diffieult beeause the recuperative, physieian-sanctioned remedies were
very rarely diseussed or highlighted in the media. Instead, patent medieines were those
drugs frequently advertised to the publie and, by definition, were those seeret reeipes that
originally won the blessing of the royalty in seventeenth- and eighteenth-eentury
England. In the late eighteenth-, nineteenth- and early twentieth-century America, patent
medieines were not offieially “patented,” but the ingredients still remained the sole
knowledge o f the maker. These patent drugs could be, and often were, a eomposite o f
many ineffective or dangerous ehemieals.
On the other hand, proprietary medieines were usually those drugs whieh physieians
and pharmacists devised, but whose primary ingredients were available to those who
needed to know a drug’s content. Most often, doetors would write a preseription for a
medieine with the full eomprehension o f all ingredients. It was also not unusual for
pharmaeists to write and provide prescriptions for patients, too. Proprietary medicines,
then, were often seen as being more ethical than the questionable patent drugs. As a
result, doetors eould simply recommend that patients avoid any medieines whieh were
openly marketed to the public because the products were patent, or quaek, drugs. For
decades the unadvertised proprietary medieations were the only doctor-reeommended
alternatives to patent drugs.
Whatever moral difference that could be said to exist between patent and proprietary
drugs, however, disappeared when the makers o f both types o f medieine began to
advertise to the general public. Once the layman beeame the target for advertising
appeals o f any drug manufaeturer, physieians and eritics denouneed the promoted

medicine as being fraudulent. The Proprietary Association o f America (PAA) tried to
defend its members’ products from being labeled as “quackery,” but they often found
themselves labeled the “patent medicine ‘combine’” (Adams 45) because critics often
saw the PAA as being part o f a larger entity which sold any drug to the public with little
concern for consumer safety. At the same time, patent medicine makers fought for their
products by claiming any restriction on advertising was a loss o f freedom for the public
(Carson 32). Once the distinction between valuable remedy and fake cure became
dangerously blurred, the FDA stepped in with strong measures intended to protect the
consumer in 1906.
Today, we face another patent/proprietary pharmaceutical industry that fosters a
proliferation o f DTCA, with many large companies spending several billion dollars per
year in advertising costs. Most pharmaceutical companies patent at least a few key
ingredients in their new prescription drugs and strive to gain brand name loyalty before
the patent expires. This desire to build a strong consumer base for their medicines
necessitates very competitive strategies on the part o f the drug makers. With FDA
regulations governing their products and advertising, these companies offer legitimate
medicines and cannot usually be accused o f quackery as patent medicine makers were
prior to FDA laws. Still, the present debate about specific advertising appeals and
situated meaning o f today’s DTCA discourse hearkens back to a time when drug
advertising to the public was considered highly inappropriate. Moreover, doctors today
can no longer use the issue o f advertising as the sole argument to convince a patient o f a
drug’s contraindication for a specific health condition.
DTCA prior to any FDA regulations that changed restrictions on prescription drug

advertising is easily plaeed along signifieant points on a timeline (see Figure 1). The
period before 1905 is a time when patent medicines were advertised to the public with
virtually no restriction by the government. The years between 1905 and 1962 are clearly
defined as important turning points in the control o f patent medicine and all
pharmaeentieal advertising. Finally, the span between 1962 and 1980 is a time when
pharmaceutical companies marketed prescription drugs solely to physieians.

1906
FDA p a s s e s P u re
F o o d a n d Drug
Act

Virtually No
FDA Control

Current Day

1951
A m endm ent limiting
m arketing of certain
drugs to physicians

DTCA still a topic of
dispute in m edical
profession

Busy F'eriod for F DA Regulation of Drugs an d Drug Advertising

1905
AM A controis
right to a d v ertise
in m edical
journals

1938
FDA p a s s e s
F ed eral Food,
Drug, a n d
C osm etic Act

1962
A m endm ent
giving FDA
g re a te r control
over DTCA

DTCA R ules
R elaxed

1980-1983
A m endm ents
allowing DTCA
with listing of
risks/side effects

Figure 1. Timeline for Regulation o f Drugs and DTCA

In 1906, the FDA acted on critical demand for federal intervention by first passing the
Pure Food and Drug Act and then later transforming this regulation into the 1938 Federal
Food, Drug, and Cosmetic Act. The 1906 Pure Food and Drug Act had only a limited
impact on drug advertising beeause it centered most o f its attention on food. The 1906
act did put restrictions on what could be printed on medicine labels, however, and
exempted any drug in the United States Pharmacopoeia from the regulation (USC 59).

This action gave the advantage to the proprietary medicines that physicians most
prescribed and thus limited the public’s access to names and messages typically featured
as an early type o f advertising on medicine bottles. Then, the 1938 Federal Food, Drug,
and Cosmetic Act, also knows as the Wheeler-Lea Act, further expanded the control over
patent medicines by limiting therapeutic claims, mandating adequate use directions on
labeling, and granting prosecutorial power to the Federal Trade Commission (FTC) so it
could take action against drug makers who advertised deceptively. The 1938 act also
created a new category o f potentially dangerous drugs that had to have a prescription
from a doctor (USC 75). Again, the FDA sent a message that drugs prescribed by a
physician were safer and that the advertising tactics o f patent medicines were to be very
limited in scope.
In 1951 and 1962, the FDA amended the Federal Food, Drug, and Cosmetic act in
ways that wrested control o f pharmaceutical advertising from the FTC. The 1951
amendment loosened some restrictions on less dangerous drugs, but maintained the
requirement for a doctor’s prescription on “habit-forming” or toxic drugs (USC 82). As a
result, the 1951 amendment also instituted strict guidelines for statements about the drugs
to include any language used on the labeling o f medicine bottles or in public statements
about the cautions and/or uses o f the drugs. As we have seen, FDA regulations through
1951 touched on advertising tangentially, but, in 1962 the FDA finally made a point o f
specifically addressing drug advertising in an amendment that regulated the listing o f all
ingredients on the label. This amendment also provided detailed requirements for
aesthetics, such as the size and placement o f the font that had to appear in the

advertisements (USC 87). The FDA guidance did not specify any restrictions on the
marketing appeals that can be used in the ads, however.

Review o f Literature on Patent and Prescription Drug Advertising
Much o f the literature on contemporary prescription drug DTCA focuses on the
historical context as well. Many books and articles detail the history o f prescription drug
advertising, explaining that the practice did not really come into favor with the FDA until
1980. Even then, the FDA was not convinced that prescription DTCA was a good idea,
but many factors influenced the FDA to acquiesce to the pharmaceutical companies’
requests for broader marketing options. Alison Huang discusses, for example, the
changing climate in terms of political and regulatory issues and the movement toward an
emphasis on the patient’s empowerment in medical decisions as key motivating factors
for prescription DTCA.
In addition to the historical information on the birth o f pharmaceutical DTCA,
existing literature establishes a context for the practice that demonstrates to readers why
the rise o f prescription drug marketing to consumers has been so rapid since 1980. One
reason often mentioned is that, since DTCA has created buy-in from the general public,
physicians now feel they must comply with customer demand. In fact, studies show that
“three quarters o f patients requesting drug prescriptions received them from their
physicians” (Huang, 2240). Because the doctors are collaborating, in a sense, with the
patients’ consumption o f prescription medications, pharmaceutical companies have
enjoyed a very profitable cost/benefit ratio in regard to DTCA. Other miscellaneous
factors also influence the increase in DTCA, such as new regulations on a physician’s

authority to prescribe specific drugs and the innovative ideas o f drug companies who find
it less lucrative to sell their products only to doctors (Kravitz).
Rather than focus solely on the background for DTCA, other literature treats the
prevalence o f DTCA as an opportunity to detail the procedures that pharmaceutical
companies should take to get their products into the DTCA arena. Devereux, for
instance, shows drug manufacturers how to effectively implement product placement and
devotes an entire chapter, “Will DTC work for your brand?” to the idea o f brand name
recognition for medicines. The pharmaceutical companies are encouraged to look at
prescription drugs as being similar to any other commercial product, like a soft drink or a
breakfast cereal. O f course, Devereux’s theory o f innovative drug promotion has raised
some ethical questions about DTCA.
Furthermore, most texts written about DTCA for both patent and prescription drugs
tend to focus on a couple o f major questions: 1) What are the ethical and legal issues o f
DTCA? and 2) Does DTCA change the doctor-patient relationship?
What are the ethical and legal issues o f DTCA?
Discussions on the ethical problems o f medicine advertising inevitably invoke the
name o f Samuel Hopkins Adams and his series o f articles written for Collier’s: The
National Weekly. Adams, an outspoken journalist, is typically credited for motivating
the federal government to move against patent drugs and to enact the Federal Food and
Drug Act of 1906 (Carson; Helfand: Holbrook; Young). In his series, “The Great
American Fraud,” Adams heavily criticizes both the patent medicine products and the
practice o f proprietary medicine advertising. The articles make no distinction between
patent drugs and proprietary remedies, saying there was not enough difference between

the two to separate the “sheep” from the “goats” (Adams 3). To Adams, any drug maker
who advertised publiely was an unethical participant in the delusion o f the public.
Adams explicitly spells out the major problems he saw with medicine advertising at
the time and spares no opportunity to name speeifie examples o f patent medieine sellers
who were defrauding soeiety. Particular targets o f Adams’s critique were the numerous
testimonials in the ads whieh greatly influeneed the seientifically “ignorant and gullible”
minds of the publie (57) and the taeties, sueh as free samples and money-baek guarantees,
which made repeat customers o f patients. As a proposed solution, Adams consistently
calls for the federal government to make needed changes in the drug market; namely, to
enforce the listing o f all ingredients on the drug’s label and to restrict the marketing o f
eertain drugs to a doctor for prescription because the doctor was in the best position to
understand the drug’s eontents.
The American Medical Association (AMA) strongly agreed with Adams on the
questionable ethies o f patent medieine advertising and included a speeial seetion in their
report o f 1908. In faet, the AMA was so coneemed about the suspect nature of
patent/proprietary medicines that they formed a Council on Pharmacy and Chemistry to
eonduet in-depth analyses o f various drugs being offered to the eonsumer. In their
findings, the AMA urged the federal government to plaee tighter eontrols on the use of
paid testimonials in all periodieals. A particular target o f criticism in the 1908 AMA
report was the apparent abundanee o f religious publieations that featured patent medieine
advertisements. Interestingly, the AMA was not the first organization to quarrel with the
religious papers who allowed pharmaeentieal advertising. Twenty years earlier in 1887, a
report from the Texas Medieal Assoeiation published the same type o f eritique stating.

“Go to the religious press and you will find it teeming with [medieine] advertisements”
(101). Both the 1887 report and the 1908 AMA report take religious leaders to task with
the remonstration that ethical preaehers did not advertise their services, so why should
ethieal healtheare providers advertise?
Although accounts of patent medieines advertising do not always pass sueh negative
judgment on the eharacter of the marketer, Stewart Holbrook makes the ease that many
were outright criminals. In fact, Holbrook titled his book The Golden Age o f Ouackerv
because he sees the period before FDA regulation as a time when unscrupulous makers o f
drugs ran rampant in soeiety. Holbrook does provide insight, however, into the
undeniable importanee o f testimonials to non-regulated pharmaceutical advertising and
forecasts a future in whieh testimonials will always play a vital role in medicine
marketing.
James Harvey Young, whose book The Toadstool Millionaires: A Social Historv of
Patent Medicines in America before Federal Regulation is often eited in diseussions on
patent medieine (Carson; Porter; Stallings), is another author who explicitly details the
successful use o f testimonials in patent medicine advertising during the eighteenth and
nineteenth centuries. In fact. Y oung’s book deseribes at length the great impact patent
medicine had on soeiety in the years before the FDA began to regulate the praetice. Like
Holbrook, Young believes that many doetors and apotheearies prepared proprietary
drugs, but only the most unserupulous o f people aetually advertised their drugs on the
open market. Hence, these individuals were seen as frauds who needed to be controlled.
Young does not analyze any drug advertisements o f the early marketing period, but he
does diseuss in general terms the marketing taeties o f quacks whieh “created the idea that

10

doctors might be deceiving the patient if they did not prescribe a medicine” (170). More
importantly, Young alludes to an undesirable time in the future when even reputable
medicine producers might be tempted to use the same advertising methods.
Literature that discusses the ethical and legal aspects o f prescription DTCA evinces
distinctly opposite viewpoints about the practice. Proponents o f prescription DTCA
assert that the practice empowers the public because patients gain confidence to speak up
for themselves in a doctor’s office and allows for better communication between doctors
and patients. In addition, pharmaceutical companies defend DTCA with the claim that
they are simply educating the public. On the other side o f the issue, opponents argue that
prescription DTCA is not providing information to patients and is only a slick marketing
tool to raise revenue for big-name drug companies.
Critics o f prescription DTCA point out that the United States is one o f only two
countries in the world (New Zealand being the other) which allows pharmaceutical
companies to advertise directly to consumers. The natural question that arises about
DTCA is why the United States does not see a problem with this marketing when the rest
o f the world is opposed to it. In response to this question, the spotlight has focused on
the conflicts that arise in the medical profession when big business (i.e. pharmaceutical
companies) has an influence on patient choice. Although pharmaceutical companies,
such as AstraZeneca and Pfizer, claim DTCA empowers consumers by making them
more assertive in their own healthcare, David Hall argues that “the cloak o f
empowerment is used to hide the maintenance o f control in the hands o f the powerful.”
Most ethical concerns about DTCA revolve around the possible conflict o f interest for
both the drug companies and the physicians (Henney; Gemperli; Murray).
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Jane Henney specifically questions if drug marketing can “serve two masters: the
promotional interest o f the pharmaceutical industry and the public’s health needs” (2242)
and refers to research that shows the risks in printed prescription DTCA are ignored by
almost 33% o f patients. The fear is that patients are convinced that they know all there is
to know about a medication when, in fact, they know very little o f the contraindications.
Marcel Gemperli points out that doctors once were the “learned intermediaries” for
patients when it came to prescription drugs, but patients today often overlook the advice
o f these physieians in their quest for the perfeet eure. Many doetors have even admitted
to eaving into the demands o f the patient in order to keep their business. Murray et al.
diseuss the ethical implications o f this pressure to please the eustomer in their researeh
whieh shows “physieians filled 69% o f requests (based on DTCA) that the doetors
themselves deemed elinieally inappropriate” (520). The study also indicates that patients
“make almost as many inappropriate requests as appropriate ones” (Murray et al 522).
From a legal standpoint, DTCA has rekindled interest in the FDA regulatory
guidelines established for the practice (Leffler; Turner). Not everyone agrees on whether
the current laws on preseription drug advertising are adequate, but the general consensus
is that caution is indicated and ehanges are necessary. Keith Leffler asserts that DTCA
ean have some positive effects on the welfare o f eonsumers but should not be treated as
an important souree o f patient information. The most frequent advice given to patients
on the subject of DTCA is to talk with a physician, which is ironically what the ads
themselves proclaim. Leonard W eber is cautiously optimistic about the potential value
for consumer education through DTCA, but advocates significant changes in the current
system. Weber proposes a change from today’s method o f FDA approval after an
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advertisement is published to a control process wherein the FDA must approve all DTCA
before it appears in front o f the public. This idea has recently gained popularity for
inclusion in a future FDA amendment.
Does DTCA change the doctor-patient relationship?
Although physicians usually made a point o f vilifying patent medicine, the general
public often embraced the language and images in the advertising. For instance, an
article in an 1881 issue o f Scribner’s Monthlv discusses the ongoing controversy of
patent medicine advertising and the doctors’ fight to prevent patients from endorsing the
drugs (Holland). The unnamed author o f the article points out that many consumers saw
no difference between the medicines advertised and the prescriptions they could obtain
from doctors. In a non-regulated market, the consumer was willing to give anyone who
could promise better quality o f life a chance. In fact, the author’s general opinion was
that the physicians were envious because they could not gam er as much enthusiastic
testimony for their remedies as the patent medicine could gather for their advertised
drugs. The fact that Scribner’s Monthlv focuses on this aspect is not surprising because
the subject o f testimonials comes up repeatedly in the study o f patent medicine
advertising.
If one issue could be said to dominate the literature on today’s prescription DTCA the
debate over changes in doctor-patient relationships would be that salient feature. The
array o f written material is clearly divided between opponents of DTCA, usually from a
physician’s perspective, and proponents o f DTCA who claim the practice is beneficial to
everyone involved.
Physicians, for the most part, agree that they are spending entirely too much time
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“dissuading patients from taking drugs that advertising has led them to believe are
unproblematic” (Huang). This additional effort on the part o f the doctor results in longer
office visits and increased medical costs. These increased costs are said to not only
impact the patient directly but also to have an effect on the insurance premiums everyone
in the general public ends up paying. A particularly worrisome aspect o f prescription
DTCA on doctor-patient interactions is the fear that physicians have about patients who
might switch caregivers if the patients’ requests for an advertised drug were denied
(Kravitz). Therefore, many physicians feel they are forced to react to the marketing
versus prescribing the medication the patient really needs the most.
This concern has led to a discussion in the last few years o f possible “medicalization”
in the minds o f today’s consumers (Hall; Am ey & Rafalovich). Under this concept,
DTCA is believed to have an undeniable influence on what patients perceive is a healthy
lifestyle. The pharmaceutical ads are said to essentially portray a “medicalized view” o f
the world in which “for every ailment there is a drug to cure it” (Carroll). Patients,
therefore, often resist the advice from their doctors to exercise or change their diets
because the patients think a pill is available to do the work for them. In situations such as
this, doctors are finding consultations with these patients to be very frustrating.
Not all o f the literature on prescription DTCA’s impact on the physician-patient
relationship is negative, however. Elizabeth Murray et al. conducted the first populationbased survey o f physicians and were the first to inquire about the doctor-patient
relationship in relation to DTCA. The results o f their study illustrate that DTCA can
have benefits for the patient because the advertising often gives the patient the confidence
to talk with their doctors. In fact, the perceived empowerment o f patients is often listed
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as the primary reason for allowing DTCA to continue (Keith). Arguments for DTCA’s
positive influence in the doctor-patient relationship also include the potential opportunity
for limiting the power physicians have regarding a patient’s choices in healthcare. Many
times, patients who are aware o f a newly available medication, and who continue to seek
further information about the drug, end up finding their own answer to a persistent
problem before their doctor does (Holmer; Kravitz). Naturally, pharmaceutical
companies agree with this view and argue that they have educated patients so they can be
more assertive in their healthcare.
As mentioned, most literature on patent medicine and prescription drug DTCA has
primarily addressed the questions already outlined. However, very few documents
actually examine the specific discourse in the ads themselves. Existing material on the
medical discourse o f print advertising is similar to Susan M cKay’s writing in which she
focuses on the language used in health risk articles in popular magazines. McKay asserts
that “the media add[s] to the understanding o f health and medicine in the lay public
through the coverage o f risk.” McKay concentrates on what the media says in magazines
versus how the advertising accomplishes its objectives. Hall does not examine DTCA
directly, but he does analyze a corpus o f medical leaflets which he asserts are nothing
more than advertisements for prescription drugs. Regarding these leaflets normally found
in the average physician’s office. Hall asserts, “it might be justified to call this sort o f
generic misrepresentation a pragmatic fraud, since its aim is to induce one kind of
reaction when ostensibly it presents itself as reassuring or disinterested (and empowering)
information.”
There are a few notable exceptions to the dearth o f discourse analysis o f DTCA
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media, however. Several articles and research studies detail the procedures for a specific
content analysis o f prescription DTCA. In one such study, Rebecca Welch Cline and
Henry Young examined the visual cues in a number o f prescription DTC ads and
provided findings on the nature and consequences o f the images placed in the ads. The
results show that certain characteristics o f the models in the ads along with the rewards
which are implicit in the photographs significantly influenced the behavior o f patients.
A second study concentrated on the implications o f “incomplete syllogisms” included
in many pharmaceutical ads (Amey & Rafalovich). This research shows that drug
companies can actually create a major and minor premise for a drug in patients’ minds,
thus influencing the patients’ conclusion that a drug is indicated for them. This point is
illustrated with ads that give consumers a number o f symptoms and then ask the
consumers to check and see if they have any o f the highlighted symptoms. In most cases,
the consumers automatically concluded that they had the specified condition and needed
the company’s advertised drug. Robert Bell, Richard Kravitz, and Michael Wilkes
performed a content analysis to examine the ways DTCA might target audiences with
inducements and appeals. The report concluded that drug companies are increasing
demand for a product, but stated further research is necessary to find the effects on
doctor-patient interaction. Cline and Young also conclude their article with a statement
indicating that, while the analysis o f visual cues was beneficial, a much broader analysis
that includes the textual elements o f prescription DTCA is necessary.
All o f the aforementioned studies, however, do not attempt to find the enduring
similarities or differences between the non-regulated drug advertising media o f the past
and a corpus o f current pharmaceutical ads, nor do the studies discuss any significant
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elements o f situated meaning. As a notable exception, Shirley Stallings specifically
draws attention to the unchanging nature o f society’s relationship with drug promotion
and details the traditions which tie today’s healthcare consumers to the patients o f an
earlier era. The patent medicine makers o f the past innovatively carved out a niche for
their products, and now pharmaceutical advertising has become a lucrative endeavor for
big-name drug companies. As the targeted audience for this enterprise, society “needs to
pay attention and maintain an awareness o f the institutions it has sanctioned” (Stallings
214). To that end, this thesis ultimately critiques the discursive techniques used to create
situated meaning in much earlier drug advertising to determine if these factors are still
active in the building blocks o f modem DTCA.

Methodology
In studying the discursive methods o f present pharmaceutical DTCA in
comparison with the non-regulated advertising o f patent medicines, I use James Paul
Gee’s theory o f situated meaning and building tasks as a qualitative foundation for
examining a corpus o f available print ads. According to Gee, situated meaning is the
concept that words depend on a particular situation to gamer meaning and that “words
have different specific meanings in different contexts o f use” (53). For each specific
situation, Gee suggests we examine the discourse for “who doing what” because there
will always be discursive indicators o f someone establishing an identity (“who”) in order
to participate in a social activity and achieve a desired outcome (“what”) (Gee 22-23). In
that regard, G ee’s theory is very similar to Kenneth Burke’s theory o f rhetorical criticism
because an agent is accomplishing a purpose through the context o f the discourse.
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At first glance, then, prescription DTCA would appear to have the same situated
meaning as the historical patent DTCA - a medicine maker (“who”) using a discourse to
sell a product to consumers (“what”). In fact, physicians typically perceive this similarity
o f situated meaning to be at the crux o f their argument against prescription DTCA and
see the practice as being an undesired throwback to an earlier time. Pharmaceutical
companies assert, however, that they are not simply selling a product and are instead
educating the public through the discourse. If this claim is true, then the situated
meaning would not be the same for patent and prescription DTCA, and the discourse o f
historical and current medicine DTCA should demonstrate key differences in
comparison. This thesis thus examines the discourse o f both patent and prescription
DTCA to determine if there is in fact any real difference in situated meaning.
When doing a discourse analysis o f this nature. Gee proposes asking specific
questions (which will be explained in later chapters) for determining how a discourse,
such as direct-to-the-public pharmaceutical advertising, might use “building tasks” (10)
to build identities, establish connections, and privilege certain types o f sign systems and
knowledge. For the purposes o f this study, patent DTCA will refer to those drugs sold by
advertising to the public prior to FDA regulation, and prescription DTCA will refer to the
current, FDA-governed marketing o f pharmaceutical companies. The following chapters
will use each o f the aforementioned building tasks - identities, connections, and sign
systems and knowledge - to compare and contrast patent DTCA’s situated meaning to
that o f today’s prescription DTCA. Although I acknowledge that innumerable over-thecounter drugs are also sold through DTCA today, the area o f primary interest for my
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study is the prescription drugs that require a doctor’s involvement because this area is
under the most scrutiny by physicians and the FDA at the present time.
We can best decide i f - as critics claim - the situated meaning of prescription DTCA
is the same as patent DTCA by breaking down the discourse o f the advertisements into
what Gee calls “building tasks” (10). Chapter two focuses solely on the building task of
“identity” (Gee 11) to uncover the ways in which authors o f the advertising discourse try
to position themselves with an audience. A drug maker can use an identity to establish
rapport with consumers in many different ways. From identity, I move in chapter three to
the building task of “connections” (Gee 13), illustrating how authors o f the discourse
make certain aspects relevant or irrelevant to the readers. The last individual building
task this thesis employs in chapter four is “sign systems and knowledge” (Gee 13) which
is vital to our understanding of the methods authors use in a discourse to privilege
specific information or awareness. Finally, chapter five pulls together the building tasks
discussed in the previous chapters to bring “validity” (Gee 113) to our analysis. This
final step is crucial, as no building task alone should completely influence our analysis,
and the interaction of individual building tasks within a discourse better enables us to
make an informed decision about the true situated meaning o f DTCA. If pharmaceutical
companies are correct in their assertion that the discourse is designed to educate
consumers about diseases and conditions, we should be able to see a significant
difference between patent and prescription DTCA.
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CHAPTER 2

BUILDING IDENTITIES
Like any other type o f discourse, pharmaceutical advertising gains or loses meaning
through its social interaction and context. Gee, in his theory o f discourse analysis, calls
this fluidity o f purpose “situated meaning” (53) and explains that a discourse’s meaning
is conveyed through images and text that correspond to a mutually agreed-upon
connotation between author and audience even though this consensus o f meaning usually
develops through an audience’s unconscious agreement. Gee asserts that we must always
look at the “who doing what” of a situation to understand how the discourse goes about
creating this flexible meaning (22).
One could simply argue then that pharmaceutical advertising, like any other type of
advertising, is deliberately designed to attract attention and sell a product and therefore
has the same situated meaning in all cases, but that position does not fully examine the
advertising discourse to determine if the situated meaning o f today’s prescription DTCA
is really the same as it was for the historical patent DTCA. We can only find the true
nature o f “who doing what” (Gee 22) by comparing patent DTCA to prescription DTCA
and d isc u ssin g the sp e c ific techniques the ads u se to accom p lish certain goals. T o that

end, this chapter will analyze the ways in which patent and prescription DTCA set about
establishing an identity with the public, looking under the surface o f the ads to uncover
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the roles and positions medicine marketers assume when conversing with consumers.
In his method o f examining discourse, Gee discusses several “building tasks” (10)
which will typically lay the foundation for any discourse’s construction o f meaning.
Each o f the building tasks carries with it questions we can ask to determine how a
discourse aligns itself under the task’s foundational concepts. Gee calls one o f these
building tasks “building identities” (11) and encourages us to answer the following
questions about identity when examining a discourse:
1) What identity (roles, positions), with their concomitant personal, social, and
cultural knowledge and beliefs (cognition), feelings (affect), and values, seem to
be relevant to, taken for granted in, or under construction in the situation?
2) How are these identities stabilized or transformed in the situation? ( I l l )
The underlying principle behind building identities is that creators o f discourse always
seek to establish a certain role they feel is important to have when speaking to an
audience. As a result, this role gains the discourse the right to have a voice in the situated
meaning.
Identity could be compared to the rhetorical appeals to ethos, but takes on a more
complex definition in the context o f Gee’s theory. While the classical appeal to ethos
involves the persuasive establishment o f qualities intrinsic to the speaker, the building o f
identity in a discourse would mean not only the personal character the discourse is trying
to establish for the author but also the authority or position the discourse wants the
audience to recognize it as having in the immediate situation. For instance, Gee uses an
example o f a person leading a business meeting to illustrate the task o f building identity.
In the context o f the business meeting, the person would behave and speak in a particular
way to gain recognition as the “chair,” but would probably not act in the same manner in
a peer interaction outside the meeting (99). The identity o f the chair would therefore be
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situated in the discourse of the meeting.
In the case o f pharmaceutical advertising, we can determine the situated meaning o f
the discourse by looking closely at the printed ads to find the identities that DTCA from
past and present construct in order to carve out a position in pharmaceutical marketing.
In selecting patent DTCA for analysis, this study selected two patent medicines - Lydia
Pinkham’s Vegetable Compound and Peruna - which received notoriety in the late
nineteenth and twentieth centuries for the amount o f money their makers spent on
advertising and for the criticism their products received in the public media. Despite the
often negative publicity, these patent medicines were very successful for many decades.
This study then used the same selection process for prescription DTCA, choosing two
drugs - Lipitor and Nexium - that are extremely popular prescription medications which
have each made billions o f dollars for their makers but have received criticism as well.
We will look at the visual and textual features o f all o f these ads to determine if they
establish identity in the same ways. Similarities would indicate - as many critics suggest
- that the discourse’s sole purpose is to sell a product. Any significant differences, on the
other hand, would indicate that a different situated meaning exists and would support
pharmaceutical companies’ claims that the discourse is intended to educate the consumer.
The best place to begin is with a well-known patent medicine to determine how it
addresses the building task of identity.
Lydia Pinkham and her family began to mass market their proprietary recipe for a
Vegetable Compound to the public in 1875, and their techniques were so successful that a
variation of the compound is still sold in some pharmacies today. This patent medicine
was touted as being effective on the “female complaints” that all women supposedly
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“suffered” (Pinkham, 1875). Typically, the ads for Lydia Pinkham’s Vegetable
Compound focus on the maladies that accompany menstrual and menopausal symptoms,
even though the medicine is also declared in the patent DTCA to be beneficial to “either
sex” when taken for “kidney complaints” (Pinkham, 1892).
In keeping with the medicine’s frequently stated indications for use, the most striking
visual aspect o f the DTCA for Lydia Pinkham ’s Vegetable Compound is the overt effort
the ads made to establish a strong identity with women in society. Ads appearing from
1881 to 1906, for example, consistently featured an illustration o f a woman at the top of
the ad where the image would be in a prominent position. The Pinkham family clearly
saw the value o f using a woman’s image in the Vegetable Compound ads because all of
their ads contained a drawing o f an elderly woman said to be Mrs. Pinkham. The
matronly woman in the illustration gazes out to the reader with the calm, reassuring
manner one would expect of a steadfast mother.
The Pinkham family continued to use this female image even after Pinkham’s death
in 1883, but they were careful to transform the visual identity to match the evolution of
society. For example, DTCA for Lydia Pinkham’s Vegetable Compound published after
1895 removed the illustrations o f the familiar elderly woman believed to be Lydia
Pinkham and replaced them with younger, more attractive “working girls” (Pinkham,
1896). The persistent visual imagery o f the ads demonstrates the patent medicine
m aker’s desire to create and maintain the identity o f a reputable, contemporary woman
speaking to other women.
The identity created in the visual elements o f the Lydia Pinkham Vegetable
Compound ads meshes seamlessly with the textual content o f the marketing. In fact,
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DTCA for this patent medicine in the years from 1881 to 1883 featured headlines in bold
text o f slogans like “Woman can Sympathize with Woman. Health o f Woman is the
Hope o f the Race” and “A Medicine for Woman. Invented by a Woman. Prepared by a
W oman” (Pinkham, 1881). One ad in particular which ran for several months in 1892,
pairs a drawing o f an elderly woman and a younger man reading through letters
(attributed in the ad to be Lydia Pinkham and her son) with 12 lines o f conversation
supposedly taking place between the two figures. In the text, Lydia Pinkham states, “The
women o f the world are my daughters, dear” (Pinkham, 1892). This heartwarming
scenario perfectly marries visual and text to portray a woman who could not possibly be
untrustworthy in her medicinal motives. Unfortunately, as many critics have pointed out,
this specific ad was printed nine years after Lydia Pinkham’s death (Bok, Adams,
Young).
Interestingly, though, the nurturing female persona o f the Lydia Pinkham ads is
somewhat subverted by the fact that Pinkham never addresses the reader directly in any
o f the ads even in the years before her death. More specifically, the lack o f first-person
pronouns or “I-statements” (Gee 141) shows a reluctance to fully engage with the
audience. This lack o f direct interaction can be compared to a speaker who will not look
into her listener’s eyes during a personal conversation. The listener is naturally going to
question the truthfulness o f the speaker’s words and the sincerity o f the speaker’s
concern. In addition, the speaker will convey the impression that she has some ulterior
motive for distancing herself from the conversation.
So rather than engaging the reader directly, an unnamed narrator consistently refers to
Pinkham in the third person, the only exception to this rule being an autograph under the
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illustration o f an elderly woman assumed to be Lydia Pinkham in the ads from 1881 to
1883 that reads “Yours for Health, Lydia E. Pinkham” (see Figure 2). This autograph is
also one o f the rare instances when the ads use a personal pronoun to directly address the
reader.

H R S. LYDli L PINKHAM. OF L7NN, MASS.,

LY D IA E . P IN K H A M ’S
VSGETABLS C0MP0Ü1TI».

Figure 2. Top o f Advertisement for Lydia Pinkham’s Vegetable Compound - 1881

Instead, the ads use first- and second-person voice to deliver positive news to the
reader in the form o f numerous testimonials from grateful female customers. The writers
o f these letters o f praise direct their comments to Lydia Pinkham and reinforce her
position as a woman who was concerned primarily about the health o f her female clients.
One ad, for example, in 1904 consists solely o f the usual drawing o f a young woman and
two such testimonials to the value o f Lydia Pinkham’s Vegetable Compound. In the ad,
one letter from a Miss Merkley commends Pinkham for “the great good you have done
me” while another letter from a Miss Claussen claims other women should “try Lydia E.
Pinkham’s Vegetable Compound” because “they will not be disappointed with the
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results” (Pinkham, 1904). The reader, therefore, is allowed to eavesdrop on the
conversation and receive sisterly advice from the testimonials. This permits the makers
of Pinkham’s Vegetable Compound to construct an intermediary with the customer.
Another important textual feature o f the patent DTC ads for Lydia Pinkham’s
Vegetable Compound is the wording the makers use to distance themselves from the
regular physicians in the consumers’ eyes. To do so, each ad from 1879 to 1906 alluded
to the unfortunate ignorance o f doctors when it came to the worth o f the patent medicine.
In the 1897 ad, the narrator states, “the usual treatment adopted by physicians.. .is
unphilosophic, unsuccessful, productive o f great suffering, and in many instances o f fatal
results” (Pinkham). A testimonial in an 1898 Lydia Pinkham Vegetable Compound ad
which ran in newspapers for several years proclaimed, “The doctor gave me medicine,
but it did me no good” (Pinkham). These references to the physicians’ purported inept
handling o f medications complicated consumers’ decisions in a time when little to no
regulation existed for the advertising o f pharmaceuticals. Thus, the image o f a warm,
motherly figure like Lydia Pinkham contrasted with the impersonal figure o f the doctor
and motivated patients to opt for the patent medicine.
If Lydia Pinkham’s target was the female consumer, then Peruna could be said to
have had “everyman” as its intended audience, as it demonstrated both visually and
textually in the patent DTCA. Peruna, another patent medicine with an enormous
following, made millions o f dollars from a diverse group o f consumers for its founder.
Dr. S. B. Hartman. Visually, the ads for Peruna support the notion that the drug was
targeting a wide range o f patients because the ads tended to use a variety o f people in its
illustrations. In the years 1885 to 1901, for example, the Hartman company changed
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each ad’s visual element on a frequent basis to show that people o f every gender, age, and
economic status were happily taking Peruna. To add further credibility, images o f
politicians. Catholic nuns, and celebrities populated the illustrations (see Figure 3).

SISTERS OF ST. FRANCIS
Use Pe-ru.na for Coughs, Colds, Grippe
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Figure 3. Top Portions o f Advertisement for Peruna - 1899 (left) and 1901 (right)

Rather than focus its energy on a limited audience, the Hartman company clearly
preferred to establish the identity o f a concerned drug maker reaching out to all members
o f society. Constantly changing the people represented in the ads not only allowed the
Hartman company to expand its eonsumer base but also sent the message that the product
was beneficial to everyone. In addition, this visual tactic provided the ads with new
sourees from which to draw praise for the medication. Even Hartman often must have
gotten earried away with the testimonials, however, beeause many crities claimed Peruna
ads featured false praise and forged letters from important members o f society (Bok;
Adams).
The textual elements o f the Peruna ads also bear a striking resemblanee to the
Pinkham ads in that we again never see the drug maker reaching out directly to the publie
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in order to sell the produet. The Peruna ads from 1885 to 1901, for instanee, never use
first-person voiee to address the readers and instead rely on testimonials from numerous
eonsumers to establish the eompany’s image. Also similar to the Pinkham ads, are the
testimonials in Peruna’s ads that are written not to the audienee but to the founder of
Peruna, Dr. S.B. Hartman. For example, an 1899 Peruna ad features a testimonial from a
Governor Atkinson who tells Hartman, “I ean reeommend your preparation, Pe-ru-na, as
a tonie.” The reader thus has a ehanee to hear the praise heaped on Hartman’s produet
without being overtly drawn into the conversation.
Hartman, in fact, does not use the first person in any o f the ads save one which is one
o f many attempts to disparage physicians. This 1886 advertisement (Figure 4) begins
with the sentence “We do not find fault, reproach, or condemn the practice o f any regular
physicians...” (Peruna, 1886) and goes on to state why a good doctor should prescribe
Peruna to patients.

T o Pbysiclans*
W e do n o t find fault, reproach or con
demn the practice of any regular physi
cian—this ISnot our mission—hut we do
claim th a t if he were to add Feruka to
his prescriptions, as directed in o ur hook
on tlie “ lils o f Life,” (and furnished g ra t
uitously b y all druggists), h o would cure
all his patients.
M r, H enry C , R eynolds, I ronton, L a w 
rence C ounty, O hio, w rites! <‘ M y wife
has been sorely distressed for m any years.
H er disease o r diseases and the symptoms
of them have been so varied th a t an a t
tem pt to describe them would be m ote
than X feel able to undertake. I Imve
paid over a thousand (i,ooo) dollars for
doctors and medicines fbr her, w itliout any
satisfactory results. W e read so much
about yo u r Perona th a t I was forced to
try it. She has now taken five bottles;
they have done her m ore good than all
the doctors and medicine th a t she has ev
er m ade use of, Peruna is certainly a
G o d * « e n d to hum anity.”

Figure 4. Top Portion o f Advertisement for Peruna - 1886
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Other, more subtle attacks on physicians are carried out in the testimonials that make
up the majority o f the layout for every Peruna advertisement. For example, the 1886 ad
also has a testimonial which asserts a patient had “consulted a number o f physicians, but
received no benefit whatever” (Peruna, 1886). In effect, Hartman uses the discourse to
undermine physicians and better position his own product with the public.
As we have seen, the makers o f both Pinkham’s Vegetable Compound and Peruna
saw the need to do similar things in constructing their identity. First, both medicines use
visual elements to highlight the loyal following each drug had generated. As a result, the
patent DTCA relies heavily on visual representations o f their existing clientele in the
discourse.

Next, both medicine makers use textual cues to present themselves as

objective parties who are offering to share the experiences o f others with the eonsumer.
In doing so, the ads for both medicines use I-statements that are action-oriented (Gee
141), meaning that the discourse only shows what the authors did instead of providing
“cognitive” or “affective” (Gee 141) I-statements which would have more personal
meaning. More specifically, the statements in the testimonials do not tell the reader how
the users o f Pinkham’s Vegetable Compound or Peruna felt or thought but rather what
they did in taking the medications. This approach to a product is what we would
typically expect from advertising’s situated meaning because it asks the reader to make a
decision based primarily on peer review while preserving the perceived objectivity o f the
manufacturer.
Finally, both patent medicine makers obviously felt it was necessary to establish a
clear division between themselves and the regular physicians when building an identity
with the public. The motivation for this decision is also a good fit for what we would
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typically expect of advertising because no manufacturer wants the customer to go to his
competitor for advice. And, the physician was definitely the competitor o f patent
medicines since the doctor was in the best position to dissuade the patient from buying
the product. Establishing themselves as being more knowledgeable than the physician,
then, would have been an extremely important role for the medicine makers to assume in
order to preserve the patent drug business.
So, the ads for Pinkham’s Vegetable Compound and Peruna build identity in ways
which coincide with what we would normally expect o f an advertising discourse. Visual
images in the patent DTCA mirror the audience the drug makers hope to attract, and the
textual elements reflect Pinkham’s and Hartman’s tendency to market the patent
medicines as a commodity versus a personal investment. This separation also allowed
the makers to avoid a certain amount o f responsibility should anyone have claimed that
the drugs were not effective. In addition, the discourse shows that Pinkham and Hartman
wanted to dissuade their audience from visiting their biggest competitor - the physician which is a logical feature o f business advertising.
Today, the authors o f prescription DTCA claim they are doing something different in
their advertising. The Pfizer pharmaceutical company, for example, stated in its 2007
report to stockholders that prescription DTCA “educates patients and is a critical
conversation starter that results in life-changing diagnosis and treatment decisions”
(Pfizer 84). Another pharmaceutical company, AstraZeneca, told stockholders in an
annual report that DTCA “plays an increasingly important role in informing healthcare
professionals and others about AstraZeneca’s medicines and the diseases they treat”
(AstraZeneca 16). If this is true, then the ways in which they build identity in the
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discourse o f prescription DTCA should be somewhat different than it was for the patent
medicines already discussed. To see if a difference genuinely exists in situated meaning,
then, we must look at prescription DTCA for the same elements o f visual imagery, Istatements and voice, and physician interaction. In selecting the prescription drugs for
analysis, this study chose Nexium, an acid-reflux drug made by the AstraZeneca
company, and Lipitor, a cholesterol-inhibiting drug made by the Pfizer company, because
both drugs have received significant publicity for the amount o f money AstraZeneca and
Pfizer have spent on advertising - $16 million in one month alone for Nexium and $11
billion in 2006 for Lipitor (Bazell, Mar 2007).
Visually, Nexium and Lipitor establish identity with the audienee in ways that might
appear ineongruous at first glance, but they contain discursive features shared by all
prescription DTCA. Nexium’s ads from 2006 and 2007, for instance, always feature
color photographs o f people from a wide range o f backgrounds, genders, etc., but the
people in the images are not eustomers who are currently taking Nexium. Instead, the
photos are o f potential patients who are said to be in desperate need o f the produet, and
an omniscient voice narrates each image warning o f the danger o f an undiagnosed
condition, such as acid reflux. Since the images are supposedly o f people who should be
taking Nexium, the ads do not have a true testimonial element as patent DTCA once did,
rather they reflect the ominously directive tone o f the aecompanying text.
This narration lets the readers feel as though they too are peering through a window
with an increased knowledge o f what may come for the poor unassuming person in the
image. One ad for Nexium, for example, shows an elderly man in a cardigan sweater
who placidly looks at the reader while the text beside the photo asserts: “Knows that his
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car isn’t the only thing that needs a regular check-up” . . .’’Knows an apple a day w on’t
always keep the doctor away” . . .’’Doesn’t know acid reflux may be damaging his
esophagus.” (Nexium, Jun 2007). AstraZeneca takes a position o f all-knowing expert in
the Nexium ads and uses discourse which allows the readers to hear the implied warning
and feel as though they now have an awareness o f medical issues that they previously had
not possessed. Using this same concept in all o f the Nexium ads (see Figure 5),
AstraZeneea appears to share a professional secret with the reader about the unsuspecting
people in the photos.
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Figure 5. Top Portion o f Advertisement for Nexium - 2006

Lipitor, on the other hand, uses the imagery in their ads in a way which is somewhat
different from the Nexium ads. The Lipitor advertisements use a eolor photograph o f a
patient. Dr. Robert Jarvik, who states he is currently using the product, so the visual is a
type of testimonial, but the appeal is made directly to the reader versus the appeals of
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patent DTCA which, as we said earlier in this chapter, were made to the drug maker. For
example. Dr. Jarvik gazes calmly at the readers from one ad (see Figure 6) and reassures
them that “Lipitor lowers bad cholesterol 39-60%. It lowered mine” (Lipitor, Dec 2007).
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Figure 6. Top Portion o f Advertisement for Lipitor - 2007

The presence of Dr. Jarvik in the prescription DTCA for Lipitor is beneficial to
Lipitor’s building o f identity for two reasons: 1) Dr. Jarvik is a patient who highly
recommends the product to other consumers and 2) Dr. Jarvik is a physician and
“Inventor o f the Jarvik Artificial Heart” (Lipitor, Jun 2007) which increases the perceived
credibility o f the spokesperson and the product. Dr. Jarvik’s reported expertise in cardiac
medicine helps Pfizer immensely because he makes a trustworthy and professional
representative for their cholesterol drug. Criticism o f Pfizer’s use o f Dr. Jarvik as a
spokesperson has included claims that Dr. Jarvik is not a practicing physician and that his
experience with the artificial heart was significantly overrated (Bazell, Mar 2007), but
this negative publicity about the marketing campaign has not affected Pfizer’s revenue
since “Lipitor hit $3.3 billion” (Bazell, Mar 2007) in sales immediately after enlisting Dr.
Jarvik’s assistance in 2005. In fact, consumers have responded so well that Dr. Jarvik is
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currently the only person featured in any o f the Lipitor ads.
In the language o f the ads, AstraZeneca and Pfizer do seem to want a closer
relationship with the consumer than patent medicines once had. In fact, the
pharmaceutical companies build an identity through the advertising which shows this to
be true. Lipitor and Nexium ads, for example, use an authoritative tone in both the visual
and textual elements o f the prescription DTCA to bolster their position in the discourse.
Although AstraZeneca begins with third-person voice for the visual aspect o f the Nexium
ads, it switches to second-person pronouns in the body o f every ad’s text. While no Istatements are used, the ads speak directly to the readers giving them an idea o f what
could happen if Nexium is needed but not used. For example, one ad states, “Unlike your
stomach, the esophagus offers little protection against acid. This means the heartburn
pain you feel is actually from stomach acid rising up into the esophagus...” (Nexium, Sep
2006). Another ad asserts, “If you suffer from acid reflux disease.. .you could have
serious damage to your esophagus and not know it” (Nexium, Jul 2006) Statements such
as these are meant to demonstrate to the reader that AstraZeneca can be trusted in its
knowledge o f medicine and in the indications for Nexium.
Pfizer begins its Lipitor ads with the images o f Dr. Jarvik speaking to the audience
and carries this first-person voice into the body o f every ad’s text. The I-statements in
the Lipitor ads come directly from Dr. Jarvik and are not only action-oriented - telling
the consumers what they should do - but are also what Gee calls “cognitive” (141)
because Dr. Jarvik gives indications o f what he thinks o f heart attacks, strokes, etc., from
a doctor’s perspective. In addition, the tone, as in the Nexium ads, is authoritative
because it speaks to the reader in prescriptive language. For example, one Lipitor ad tells

34

the reader, “if you take LIPITOR, tell your doctor if you feel any new muscle pain or
weakness” (Lipitor, Dec 2007). Another ad directs the reader to find more information
about the medicine through Pfizer’s website.
Another aspect o f building identity that appears to be different in the text o f
prescription DTCA is the interaction with physicians that the pharmaceutical companies
demonstrate they want to have. Whereas the patent DTCA from the past attempted to
build a separate identity from the doctors, the prescription DTCA makes several attempts
in each ad to exhibit professional goodwill toward physicians. Nexium ads, for instance,
repeatedly use lines such as “Ask your doctor if NEXIUM is right for you” and
“ .. .discuss it with your doctor” (Nexium, Sep 2006) throughout the text. O f course,
maintaining an image o f collaborative effort with physicians is important if the company
hopes to have its medication sell. After all, physicians must prescribe Nexium and
Lipitor if a patent is to take them, and AstraZeneca and Pfizer are careful not to bite the
hand that feeds them.
To that end, Lipitor ads use similar language, but are interesting in the way they
continue to have an authoritative voice even while referring a patient to a doctor. For
example, after directing the consumer to see a doctor, one Lipitor ad states, “Your doctor
should do blood tests to check your liver function before and during treatm ent...”
(Lipitor, Dec 2007). The pejorative use o f the word “should” in this line in relation to
what a proper doctor would know to do indicates that Pfizer still feels it has the upper
hand in the discussion o f Lipitor and wants to convey this position to the public.
An element o f today’s prescription DTCA which is impossible to compare to the
patent DTCA is the full page, or often several pages, of text on the reverse side of the
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printed ads that describes the side effects and risks o f the prescription medications.
Historically, the patent DTCA never had this feature because the patent drugs were not
regulated in any way. The FDA, however, now requires that all “product-claim” ads those prescription ads that feature both a medicine’s name and indications - include a
lengthy textual component that provides consumers with important information about a
drug. In this component o f the prescription DTCA, however, we usually see the drug
company’s desired image - a concerned corporation speaking directly to a potential
patient - diluted by the accompanying legal requirements o f the text. Nexium ads, for
example, commonly begin the reverse side o f their ads with the warning to “ask your
doctor about NEXIUM” (Nexium, Sep 2006). From that point on, the ads revert to a
detached third-person narrative filled with technical language and legal terms. Likewise,
the Lipitor ads begin the text for side effects and risks with a conversational tone but
quickly evolve into a very authoritative voice with statements that begin with prescriptive
words such as “Do n o t...” and “T ake....” Pharmaceutical companies therefore have an
interesting convolution o f identities happening in a single discourse due to the FDA rules.
As one can imagine, building an identity in the prescription drug market today is vital
to a pharmaceutical company’s success, and ironically FDA rules sometimes make
establishing this identity easier for a drug maker in the discourse o f the ads. For example,
one common way for a pharmaceutical company to establish its identity is in the strategic
placement o f ads that don’t even address a particular medical condition. Instead, these
ads, categorized as “reminder” (Weber 160) by the FDA, are allowed to mention only a
brand-name drug but not a specific disease, condition, or guidelines for use. By FDA
regulation, these reminder ads can refer a consumer to a physician, but they cannot
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address any particular indications for the prescription drug in the ad. Therefore, while the
content of the reminder ad is not designed to overtly sell medicine, it nevertheless invites
the public to associate a company’s brand name with a positive image.
AstraZeneca, like many other pharmaceutical companies, has found an innovative
way to build its own identity with DTC reminder ads. Although AstraZeneca follows the
FDA rules in these ads by including the Nexium name, it also takes the opportunity to
pitch the company’s ethical appeal. W ith this unique combination o f reminder and
corporate-identity advertising, AstraZeneca tries to build its positive ethos by showing
what the company is doing to be socially responsible. For example, in one such reminder
ad, AstraZeneca tells readers “NEXIUM users don’t have to go far for free support” and
encourages the reader to “Be part o f Purple Plus - a free program for NEXIUM users”
(Nexium, Sep 2006). The ad then goes on to tell the reader how AstraZeneca can help
them save money when purchasing the drug. Although this particular Nexium ad does
mention getting advice from doctors, these hybrid ads often omit any reference to a
physician and could be compared to public service announcements from agencies who
profess an altruistic dedication to overcoming a social dilemma.
AstraZeneca and Pfizer are very diligent about carrying over the positive image
created in their reminder ads to the text o f their more traditional ads. All product-claim
DTCA for Nexium, for instance, contains a three-line entry at the bottom o f the ad that
reminds the reader about N exium ’s “Purple Plus Program” encouraging the reader to call
for more information. The small print under this reminder informs the reader that
AstraZeneca might be able to help users o f Nexium with their prescription costs. Pfizer
uses the same concept in its product-claim DTCA for Lipitor, ensuring the reader knows

37

about its “helpful answers” (Lipitor, 2006) program that can help uninsured patients with
funds for their Lipitor prescriptions. So, pharmaceutical companies like AstraZeneca and
Pfizer now use FDA rules to create a unique marketing situation wherein the image o f
monetary assistance from a benevolent company is clearly highlighted for a needy
customer.
As consumers, however, we must remember what Samuel Hopkins Adams said in
The Great American Fraud —“It is safe to assume that every advertising altruist who
pretends to give out free prescriptions is really a quaek medical firm in disguise” (62) beeause the discourse o f prescription DTCA should not always be accepted at face value.
After all, the FDA continues to enact laws which strongly regulate the marketing
practices o f prescription DTCA. So, while AstraZeneea and Pfizer do appear as though
they are acting out o f concern and compassion in their advertising discourse, they also
include specific textual elements simply beeause the FDA tells them they must do so if
they want their ads published. For instanee, the rejoinders in the prescription DTCA to
“see your doctor” or “discuss this medication with your doctor” are not altruistic
decisions made solely by the pharmaceutical companies. Rather, the FDA mandates that
these types o f statements be included in every product-elaim ad that is published in the
mass media.
In terms o f situated meaning, however, prescription DTCA does reflect key
differences compared to patent DTCA in the way both discourses build identity. The ads
for Pinkham’s Vegetable Compound and Peruna, for instanee, exhibited language which
made them sound more like second-hand news from a disinterested reporter. We also
saw how the patent DTCA used imagery and language to highlight the patients who were
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already taking the medication, hoping that the testimonials would have a bandwagon
effect on other consumers. Apparently, the patent drug makers did not feel that they
needed to engage directly with potential consumers or include them in a discussion in
order to sell the medication. In effect, the patent DTCA does not give the impression that
the makers genuinely eared about the readers.
The visual and textual eomponents o f the preseription DTCA, on the other hand, do
indicate the drug makers’ desire to include the reader in the marketing and typically
focuses on people who are not taking the medication. This shows that the pharmaceutical
companies feel the need to insert themselves in a dialogue with potential patients in a
way that makes the eonsumers feel as though they are involved in a medieal decision
versus simply engaged in a commereial produet selection. This interaction with
consumers would support the pharmaceutieal eompanies’ position that they are using the
advertising diseourse to edueate the publie.
Therefore, the preseription DTCA does seem to be undertaking a diseourse within a
situated meaning that is somewhat different from the context o f the patent DTCA;
however, we must be careful about agreeing to this differenee after only looking at the
building task o f identity. Establishing identity is only one o f many behaviors occurring
within a discourse, so we must look at other building tasks to fully validate an analysis.
Therefore, for pharmaceutieal advertising, we ean also look at the ways in which the
DTCA builds eonnections, and the next chapter will diseuss this aspect o f the diseourse.
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CHAPTER 3

BUILDING CONNECTIONS
As previously explained, a discourse clarifies its situated meaning - the “who” doing
“what” - through its construction o f certain “building tasks” (Gee 10). This thesis has
already shown how a discourse like pharmaceutical advertising establishes its identity
and what the authors’ position can tell us about the context and desired effect, but we also
need to look at other building tasks to truly determine a particular situated meaning. The
building tasks function independently, but they also work in combination to signify a
context. To that end, this chapter focuses on the building task o f “connections” (Gee 1213) to analyze pharmaceutical advertising and determine if the situated meaning o f
prescription DTCA is any different - as the pharmaceutical companies often claim - from
the situated meaning of the advertising discourse used for historical patent medicine.
Just as he did in his explanation on the building task o f identity. Gee provides us with
several questions about connections that any good analysis o f a discourse will ask. In
regard to building connections. Gee suggests we examine a discourse with the following
thoughts in mind:
1) What sorts o f connections —looking backward and/or forward —are made
within and across utterances and large stretches o f the interaction?
2) What sorts o f connections are made to previous or future interactions, to other
people, ideas, texts, things, institutions, and Discourses outside the current
situation?
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3) How do connections.. .help (together with situated meanings and Discourse
models) to constitute ‘coherence . . .. (112)
Asking these questions will help us determine how a discourse makes its content
pertinent (or not) to a current or future situation. To further explain the concept of
building connections, Gee returns to his example o f the person leading a business
meaning (discussed in this thesis in chapter 2). In the context o f the business meeting,
the person leading the meeting behaves and speaks in a particular way to gain recognition
as the chair; thus the identity o f the chair is situated in the discourse o f the meeting. At
the same time, the person leading the meeting would use specific language to make what
he/she says during the course o f the meeting relevant (or not) to a time outside o f the
meeting (Gee 100-101). For example, if we wanted people attending a meeting to, at a
future date, make an operational decision about hiring practices based on the company’s
vision, we would need to ensure we use language in the meeting that could help the
attendees draw that connection later. In a way, building connections is similar to planting
a seed in a discourse and then implying to an audience why they should help that seed
grow. In doing so, discourses often use emotional appeals to pathos to bolster the
connections they create.
A discourse can build (or break, for that matter) certain connections in many different
ways. Gee states that he prefers to start looking for connections by first finding the
“motifs” (153-155) that seem to act as running themes in a discourse because the motifs
indicate ideas the author wants to reinforce with an audience and tie different parts o f the
discourse together. As this is a good place to start, this chapter will look for the motifs in
pharmaceutical advertising, again using the patent DTCA for Lydia Pinkham’s Vegetable
Compound and Peruna along with the prescription DTCA for Nexium and Lipitor as
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specific artifacts for study. Using these same ads throughout this thesis is important
because we must remain consistent in the analysis examples we use if we want to reach a
valid conclusion. In the process o f finding language that establishes motifs, this chapter
will also explore how the construction o f the discourse’s language helps make it easier or
more difficult for an audience to find relevance in the advertising. We will pay particular
attention to the use o f syllogisms and phrasing in both patent and prescription DTCA
because these textual elements often are the most effective at facilitating an audience’s
acceptance o f a drug (Amey & Rafalovich). Marketers often rely on syllogistic premises
in the text to help a reader reach a conclusion that seems logical.
Returning to the patent medicine o f the past, we find that common motifs existed in
the advertising for both Lydia Pinkham’s Vegetable Compound and Peruna. The first o f
these predominate motifs was that certain health issues were universal to all readers. For
the Pinkham company, this appears to have meant that simply being o f the female gender
was a health issue because the advertisements usually stated the patent drug was good for
all manners o f “female complaints” (Pinkham, 1879) or “female weaknesses” (Pinkham,
1883). In making such female problems more specific for the reader, the DTCA for
Pinkham’s Vegetable Compound typically described a wide variety o f health issues that
were open to interpretation. For example, the ads from 1879 to 1906 contain references
to everything from fibroid tumors to women’s “organic derangement” which a 1906 ad
said was particularly terrible (see Figure 7). This ad was amazingly comprehensive in its
indications when it stated the patent drug was good for:
Irregular suppressed or painful periods, weakness, displacements or ulceration,
that bearing-down feeling, inflammation o f the female organs, backache, bloating
(or flatulence), general debility, indigestion and nervous prostration, or...such
symptoms as dizziness, faintness, lassitude, excitability, irritability, nervousness.

42

sleeplessness, melancholy, “all gone” and “want-to-be-left-alone” feelings, blues,
and hopelessness. (Pinkham, 1906)
With such a disparate list o f symptoms, the ad effectively made it possible for any
woman to see that she should include herself in the vast majority o f female consumers
who have what Pinkham’s medicine terms significant health problems.
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Figure 7. Advertisement for Lydia Pinkham’s Vegetable Compound - 1906

For its patent DTCA for Peruna, the Hartman company took the same approach on
this theme that conditions were universal and that everyone suffered at least one o f the
drug’s stated indications. In fact, p in n in g d ow n a sp ecific illn ess that Peruna w as

designed to treat is difficult because the ads from 1885 to 1901 ranged from discussions
o f “catarrah” (Peruna, 1885), which is essentially a form o f sinus congestion, to “kidney
complaint and dizziness” (Peruna, 1886) and “fever and ague” (Peruna, 1901). The
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patent DTCA for Peruna even gave a nod to the same premise the Pinkham ads
established for female problems by linking Peruna to “female catarrh” (Peruna, 1899) asserting women have sinus congestion that differs vastly from that o f a man - and the
“weaknesses peculiar to” the female sex (Peruna, 1899).
Overall, however, the Peruna ads consistently showed audiences o f all ages and
genders that certain health issues were common to society as a whole. In keeping with its
“everyman” identity (as discussed in chapter 2) when building connections, Peruna used
wide-ranging conditions that were sure to have at least one link to each person. Thus the
wording o f the patent DTCA across multiple examples conveys the coherent thought that
consumers should see their own health as connected to that o f others with the same
symptoms. Establishing this bandwagon connection was important in the situated
meaning o f patent DTCA because the audience was able to see themselves in the
discourse and relate their own everyday experiences with the effects mentioned in the
ads.
The next m otif - that everyday health issues, although common, were not conducive
to a happy life and needed to be “cured” - ran throughout the patent DTCA discourse to
connect the illness to the medicine. In the ads for Lydia Pinkham 's Vegetable
Compound, for example, the word “cure” was used repeatedly in each ad to show what
the medicine supposedly had the power to do. In fact, one ad began with the large-font
heading “Female Complaints and successful METHOD OF CURE” (Pinkham, 1879) and
employed a version o f the word “cured” a total o f eight times in a single 2x8-inch space.
By telling readers that Lydia Pinkham's Vegetable Compound could cure “the blues”
(Pinkham, 1906) and other vague symptoms, the patent drug makers effectively sent the
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message to consumers that what they might be feeling was not acceptable and therefore
had to be fixed. O f course, the only way to correct the problem, according to the drug
maker, was to use the advertised patent drug.
To someone who is closely reading the patent DTCA, the two motifs o f common
conditions and necessary cures might appear incongruous at first. The natural question
would be: How could readers accept that health issues shared by all could also be
abnormal? The answer resides in the syllogism which results from the patent DTCA’s
construction. The first motif, for instance, establishes the major premise that all people
share a certain set o f physiological or emotional conditions. Readers can easily situate
themselves within this premise because they correspond to the targeted group. The
second m otif then establishes the minor premise that the stated condition means
unnecessary suffering that can be “cured” with the advertised drug.
The major and minor premise, working together, lead readers to make the concluding
premise that they have the condition and need à remedy. In the Pinkham ads, for
example, after telling a female consumer that 1) All women have particular health issues
(major premise) and that 2) These issues do not need to be endured and can be cured with
the Vegetable Compound (minor premise), the discourse silently encourages the female
reader to reach the conclusion o f “I am a woman. I have this problem, so I need this
medicine - and lots o f it - in order to live well.” A Peruna testimonial made this type o f
syllogistic construction evident in the simple statement, “If others who have been sick are
now well and happy, why shouldn’t you be?” (Peruna, 1889). Using language to
“medicalize” a perfectly normal health condition, the patent drug makers benefited from
society’s ability to make assumptions. James Young points out that patent DTCA
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“recognized that nearly every man is vulnerable to the power o f suggestion and sought to
make him sick so they could make him well” (184). As we will see later in this chapter,
drug makers are still using syllogistic construction to accomplish the same goal.
In the ads for Peruna, the Hartman company again mirrors the efforts of the Pinkham
ads in the m otif that common conditions degraded a consumer’s quality o f life and had to
be eliminated. The Peruna ads also employed repetitive language, such as the word
“eure,” to connect various health problems to the recuperative effects o f the drug. One
such ad begins with the heading “A FAMOUS MUSICIAN Cured o f Catarrh and La
Grippe by Peruna” (Peruna, 1901) and continues in a testimonial to say how glad the
person is that the wonder drug has at last cured him o f his problems. Another Peruna ad
goes even further in linking illness to a eure in a testimonial which asserts, “It has robbed
the grave o f one victim, for I was in a critical condition...” (Peruna, 1899).
The unique aspect o f the Peruna patent DTCA, however, is that the discourse o f the
ads not only ties the drug to possible problems the readers might have had, but also draws
a strong correlation to the amount o f the so-called cure which might be necessary. In
very specific language, the Peruna ads tell the audience that using multiple bottles o f the
patent medicine would be the best way to eradicate a health concern. For example, an
1885 ad mentions that a woman “has now taken two bottles, and is so much better that
she will never quit its use until she is entirely w ell” (Peruna, 1885). Another ad a year
later features a testimonial about a woman who “has now taken five bottles...” (Peruna,
1886). This language continues throughout the Peruna ads often mentioning the use of
several bottles o f the drug (see Figure 8) and in 1899 culminates in a testimonial wherein
a woman claims she has “taken ten bottles o f your Pe-ru-na and will continue taking it...”
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(Peruna, 1899). None o f the ads ever address, however, why multiple bottles or
continued use might be necessary if the drug was, in fact, a genuine cure. O f course,
critics often pointed out that Peruna was approximately 28 percent alcohol (Adams;
Young; Bok) and Lydia Pinkham’s Vegetable Compound was around 20 percent alcohol
(Bok), so patients were often willing to take more and more o f the products with very
little encouragement beyond the first bottle.
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Figure 8. Advertisement for Peruna (aka Pe-ru-na) - January 1899

While the patent DTCA for Peruna might have been somewhat humorous in its
methods to sell increased amounts o f its product, the advertising discourse has a more
serious effect in building connections. Gee points out that a discourse has the power to
influence what he calls “prototypical simulations” (95-96). A prototypical simulation is
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the image or story that a person carries in his/her mind about what a typical situation
would look like. The person then uses this simulation to determine whether something is
“normal” or not. For instance, each o f us has a prototypical simulation o f what is typical
or normal for a wedding or for parenting, etc (Gee 95-96). If we were to then attend a
wedding that did not match up with our prototypical simulation, we would either be
confused by the juxtaposition or we would have to adapt to the change.
In the same way, patent DTCA established connections which may have influenced
consumers’ prototypical simulations about healthcare. More specifically, the advertising
for both Peruna and Lydia Pinkham’s Vegetable Compound demonstrated an effort to
change what readers comprehended as being normal for everyday health. For instance,
what women may have originally seen as just being a bad mood became - through patent
DTCA - normalized as a problematic and worrisome female issue. After the consumers
made the shift in their thinking to what should he normal or typical, it was a short jump
for them to assume it was then normal to need large doses o f an advertised medication.
At this point, we might expect an audience to seek a doctor’s advice before blindly
accepting the need for a medicine, but the patent DTCA used a final m otif which served
to break or mitigate any connection readers might have had with a physician. In fact, the
discourse made the need to see a doctor irrelevant with statements that showed the
“medical arts” (Pinkham, 1879) had been ineffective and thus were not necessary. Lydia
Pinkham’s Vegetable Compound ads typically broke the connection between patient and
doctor by stating frequently that the “female complaints” had “baffie[d] the skill o f the
best medical men” (Pinkham, 1885) and that doctors gave medicine which had no effect
on the illness (Pinkham, 1898). Interestingly, a Pinkham ad in 1883 departed from this
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approach by claiming “PHYSICIANS USE IT AND PRESCRIBE IT FREELY,” but the
Pinkham family, under heavy scrutiny, quickly dropped this line from the advertising the
following year.
The Peruna ads followed suit in the effort to disrupt the patient/physician relationship
and often discussed the futility o f seeing a doctor. A testimonial in 1885 informed the
reader that the patient “had consulted every physician far and near” (Peruna, 1885).
Obviously, since the patient was now speaking on behalf o f Peruna, the doctor visits had
been unsuccessful. Another testimonial in 1886 proclaimed, “I have paid over a thousand
(1,000) dollars for doctors and medicines...without any satisfactory results” (Peruna,
1886). Thus the reader is encouraged to save money on doctor bills and buy multiple
bottles o f Peruna instead. Later Peruna ads were even more overt in their attempt to
dissuade consumers from visiting doctors. Statements such as “I did not call the doctor,
but used your medicine” (Peruna, 1899) littered the text o f patent DTCA to further the
drug makers’ efforts to make traditional medical care irrelevant.
As we have seen, in terms o f situated meaning, the patent DTCA built connections in
ways that correspond to the basic advertising context o f a manufacturer marketing a
product to the public. In this case, the drug makers primarily wanted to increase sales by
showing audiences they absolutely needed their medicine. The first step in doing that
was to help the consumers see that they were part o f the population who had a certain
condition. Next, the advertising had to guide the consumer into the realization that the
product would help overcome the health problem they possessed. To accomplish this,
Lydia Pinkham’s Vegetable Compound and Peruna worked to make the consumer feel
included through syllogistic reasoning. Finally, the advertising sought ways to prevent
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any interaction potential buyers might have in the future with the competition - who in
this ease was the physician. Doing so effectively loeked the buyers into repeated
transaetions with the manufaeturer.
Like patent DTCA, advertisements for today’s prescription medications also build
connections in the diseourse, so we ean turn to the ads for Nexium and Lipitor to
determine how the eurrent pharmaeeutieal companies make eertain elements relevant (or
not) to the public. Just as we did with the DTCA for Pinkham’s Vegetable Compound
and Peruna, we will look for the motifs featured in the ads along with the construction o f
the textual elements.
In the first noticeable motif, we can certainly hear eehoes o f the historical patent
DTCA because the most salient feature o f preseription DTCA is the theme that readers
are not aware o f the health dangers that are eommon to our society. AstraZeneea, for
example, uses language that implies no matter how well a person thinks he/she is
managing acid reflux, serious problems are still imminent. The Nexium ads, as we
discussed in ehapter 2, typieally begin with the visual image o f a normal-looking person
who is blissfully unaware o f how much he/she might be in jeopardy. We said this image
helps AstraZeneea draw the audienee in as a silent observer to this person’s woes.
To help build a connection, however, the drug maker switehes in the text o f the ad to
statements such as, “Even if you’re treating your heartburn, you may still have damage”
(Nexium, Sep 2006) and “If you suffer from aeid reflux disease...you eould have damage
to your esophagus and not even know it” (Nexium, Jan 2007). The ads now enable the
consumer to make the leap from bystander to aetive partieipant by appealing to the fear
readers might have o f their own undiagnosed problems. One ad for Nexium espeeially

50

plays on this fear by stating, “IT’S DIFFERENT FOR PEOPLE WITH ACID REFLUX
DISEASE. Because beneath the heartburn, something more could be brewing” (Nexium,
Jul 2006). Suddenly, readers make the connection that their oeeasional episode of
heartburn - whieh, in faet, might result from a bad meal - is nothing less than the chronic
condition exhibited in the preseription DTCA. They begin to see themselves as the
unfortunate person in the ad’s graphie. If readers were to look more elosely at the text of
the Nexium ads, however, they eould see that AstraZeneea also seleets its wording very
earefully.
In faet, today’s pharmaeeutieal companies are much more cautious than the patent
drug makers were in the wording o f the diseourse. The patent DTCA was unregulated, so
just about any el aim could appear in the ads with impunity. Preseription DTCA,
however, must conform to FDA laws or it can and will be held liable for false or
misleading statements. This is not to say that the ads do not manipulate shades of
meaning, however. The language in the prescription DTCA, for instance, consistently
takes advantage o f numerous modal words like “eould,” “may,” and “might” throughout
the advertising space to not only avoid any absolutes whieh might violate FDA regulation
but also defleet any blame for misdiagnosis. A good example o f this concept is a line
which appears in every Nexium ad - “This condition may affect 1 in 3 people with acid
reflux disease, and if left untreated, could get worse” (Nexium, Jun 2007). This wording
choice maintains the ads’ relevance for possible users of Nexium while not specifically
telling the consumers that they have a problem. The phrasing o f sentences in Nexium
ads also evinces a tendency to place a warning about imminent danger above the more
comforting words of the discourse. For example, the common heading in Nexium ads -
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“Even if you’re treating your heartburn, you may still have damage” (Nexium, Jun 2007)
- phrases the information in such a way that emphasis is placed mainly on the potential
damage and discounts the fact that the patient might be trying to treat the condition
already.
Pfizer, in its Lipitor DTCA, is slightly more encouraging on this m otif o f cautioning
the ignorant consumer but, like the Nexium ads, still seems to offer more warning than
enlightenment. The Lipitor ads typically list a number o f items they identify as risks for
heart disease and tell the readers that they could be in danger if they have “multiple risk
factors” (Lipitor, Jul 2006). These factors range from something as arbitrary as “age” to
more specific issues such as “high blood pressure” (Lipitor, Dec 2007). The confusing
aspect with this approach, however, is that some Lipitor ads state the patient would need
to show “multiple risk factors” - no quantifiable number is given - to need Lipitor, while
other Lipitor ads state the patients would only need “type 2 diabetes and at least one other
risk factor” (Lipitor, Nov 2007) to be a candidate for the drug. This discrepancy leads the
consumers to resolve the difference by erring on the side o f caution and accepting the
need for the drug on the smallest provocation. In fairness, this study found that the
Lipitor ads do let readers know that Lipitor may not be indicated in some cases, but only
lists “those with liver problems” and “women who are nursing, pregnant, or may become
pregnant” (Lipitor, Dec 2007) as the exemptions. This, o f course, leaves a large
population who could be potential buyers o f the drug, and the wording throughout the
Lipitor ads helps make that choice more obvious.
Once patients acknowledge that they probably have to be concerned with one o f more
o f the health issues identified in the prescription DTCA, they will notice the next m otif
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which appears in the advertising discourse and is very similar to the non-regulated patent
DTCA - the realization that only the advertised prescription drug will help them. To that
end, Pfizer goes to great lengths in the discourse to make sure the public sees Nexium as
being very relevant to an acid-reflux condition. The image o f an actual Nexium capsule
appears at prominent positions within the textual component o f each ad to reinforce the
medicine’s shape and color for the readers (see Figure 9).
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Figure 9. Bottom Portion o f Advertisement for NexiUm - 2007

In addition, the words, “The Little Purple Pill,” run through every ad and even show
up in the name o f the customer-service website - www.purplepill.com - for the
medication. These words and graphics work together to solidify the connection in the
consumers’ minds between their condition and the medication that they should request.
AstraZeneca also includes references frequently throughout the ads to the recuperative
power o f Nexium with statements such as “NEXIUM is the healing purple pill” (Nexium,
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Jul 2006) and “it [Nexium] can also heal the most severe erosions in the esophagus...”
(Nexium, Jun 2007). The ads do not mention whether any other options are available for
treatment.
Pfizer structures its ads for Lipitor to accomplish the same objective o f brand
recognition. Lipitor is strongly portrayed as being the answer to the consumers’ eoneems
about heart disease and cholesterol. To support these claims, all o f the DTCA for Lipitor
pictures Dr. Robert Jarvik - again personifying the Pfizer corporation as part o f the
company’s identity —offering numerical data such as “Lipitor lowers bad cholesterol 3960%” (Lipitor, Dec 2007) and “Lipitor reduces risk o f stroke by 48%” (Lipitor, Dee
2007) whieh serve as a convincing “scientific” tool to equate efficacy with the drug.
Each Lipitor ad also includes the line “Lipitor is one o f the most researched medicines
with over 400 ongoing or completed clinical studies” (Lipitor, Nov 2007).
O f course the Lipitor ads do not make relevant the faet that there have been so many
studies of the drug partly because it has been under heavy scrutiny by the FDA. In faet,
several lawsuits in the past have taken Pfizer to task for the claims in the Lipitor ads,
including one suit whieh recently even tried to subpoena Dr. Jarvik. This suit, filed in
April 2007 by several labor unions, accuses Pfizer o f knowingly using language in the
Lipitor ads whieh resulted in a large number o f patients requesting (and often receiving)
the drug when it was not indicated. The litigation primarily centers on wording that
shows Pfizer marketed the drug to consumers with an “LDL cholesterol level o f 130
ml/dL” when medical professionals suggest cholesterol levels only indicate intervention
at “ 160 ml/dL” (Edwards 14). The labor unions insist that Pfizer’s ads have resulted in
approximately 40 million people taking Lipitor when not medically necessary (Edwards).
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The statistics have been in dispute for a while now, but the numbers are unquestionably
persuasive to readers who make conclusions on what they believe is scientific
information. In addition, Pfizer’s “helpful answers” campaign - mentioned in our
discussion o f identity because the reference is included in every Lipitor ad - aets here as
a bridge since the customer now not only remembers the company as having a positive
image but also connects that positive ethos to convincing numerical data in their attempts
to make a logical healthcare choice.
In helping readers make selections, the construction o f the sentences in prescription
DTCA shares much in common with the patent DTCA. Earlier in this chapter, we said
patent DTCA helped normalize common feelings, such as a bad mood, into what people
came to see as a condition that needed to be treated. This same concept works in today’s
preseription DTCA as consumers change their prototypical simulations o f illness based
on the advertising they read. Like the patent advertisements, prescription DTCA often
uses syllogistic language to accomplish this change in normality. To explain this idea,
Jennifer Am ey and Adam Rafalovich conducted a study o f prescription DTCA that
showed the overwhelming use o f “incomplete syllogisms” (49) in the wording o f the
advertising made a significant difference in the “medicalization” (50) o f health
conditions. According to Amey and Rafalovich, prescription DTCA almost always
offers a major premise which invites readers to identify with stated conditions. Then, a
minor premise helps frame the condition as being symptomatic o f a condition needing a
medicinal remedy. The concluding premise is unstated, but the major and minor
premises work together to convey “a narrative that paints the concluding premise as
almost inevitable” (Amey and Rafalovich 57). The ads for Nexium and Lipitor exhibit
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this type o f construction mainly in the form o f hypothetical syllogisms - premises that
use an “i f ’ statement - that range from “If you suffer from aeid reflux...” and “if left
untreated...” (Nexium, Jan 2007) to “if you have multiple risk factors...” (Lipitor 2006).
Pfizer, for one, asserts that its DTCA helps “de-stigmatize disease” (Magee 4), but
leading consumers to a conclusion also changes their expectations.
In terms o f breaking or mitigating connections, preseription DTCA does not follow
patent DTCA in its efforts to disrupt the relationship with physicians, but the current ads
do make certain information irrelevant in the discourse. O f course, we must first
remember that the FDA mandates the inclusion o f statements like “talk to a doctor,” so
the historical ads had more freedom to discount doctor intervention. Preseription DTCA
instead typieally downplays options, other than the advertised drug, whieh exist to
manage a condition. One clear example o f this approach is to mitigate the importance o f
diet and generic drugs. AstraZeneca’s ads for Nexium always begin with the message
that aeid reflux “despite treatment and diet change” (Nexium, Jan 2007) could be
damaging the reader’s esophagus while Pfizer’s ads for Lipitor ensure patients know that
“diet and exercise” (Lipitor, Dec 2007) may not be enough to avoid the need for
medicine.
Nowhere in the advertising diseourse for either company is any information to
educate consumers on the proper diet they should consider or the availability o f other
medications. In fact, Kravitz notes that “patients may become angry when their
physician insists on a low-fat diet...” and “ 1 study found that as many as half o f patients
would register disappointment, and 15% would consider switching physicians, if their
physician refused a request for an advertised prescription medication” (Kravtiz 2244). In
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regard to forms o f treatment other than the advertised drug, Dr. Robert Jarvik is featured
in one Lipitor ad telling the audience that “I take Lipitor instead o f a generic; There is no
generic form o f Lipitor. If you switch, it will be to a generic o f a different medication”
(qtd in Huckman 1). Language such as this strongly devalues less expensive options than
Lipitor in the consumers’ minds and enables Pfizer to continue posting Lipitor sales o f
over $13 billion per year (Bazell, Mar 2007).
Interestingly, prescription DTCA also mitigates the very elements which would
support pharmaceutical companies’ claims that they might be educating the public in the
discourse. For instance, the reverse side o f the product-claim ads (see Figure 10) that
must contain the listing o f side effects and risks has the potential to convey extremely
important information to consumers.

Figure 10. Reverse Side o f Advertisement for Nexium - Sep 2006
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In the Nexium ads, however, this text is so crowded and linguistically dense that many
patients - up to one-third according to Henney - do not even attempt to read the
information, thus making the print practically irrelevant to the situation. Instead, patients
simply remember the drug’s brand name and go to doctors asking for the medication with
only a surface understanding o f the details.
In the case o f Lipitor advertising, the design o f the reverse side o f the product-claim
DTCA has the potential to make the most serious side effects o f the drug irrelevant to
both patients and physicians. In 1979, the FDA hegan to mandate that pharmaceutical
companies place “hlack hox warnings” (FDA 9) on labeling to indicate the most severe
side effects o f a particular drug. As part o f that requirement, drug makers must include a
hlack border around the text that informs readers o f the most dangerous aspects o f a
medication. According to FDA guidelines, the hlack hox warnings are supposed to
indicate that;
There is an adverse reaction so serious in proportion to the potential benefit from
the drug (e.g., a fatal, life-threatening or permanently disabling adverse reaction)
that it is essential that it he considered in assessing the risks and benefits o f using
a drug
OR
There is a serious adverse reaction that can be prevented or reduced in frequency
or severity by appropriate use o f the drug (e.g., patient selection, careful
monitoring, avoiding certain concomitant therapy, addition o f another drug or
managing patients in a specific manner, avoiding use in a specific clinical
situation)
OR
FDA approved the drug with restrictions to assure safe use because FDA
concluded that the drug can he safely used only if distribution or use is restricted
(e.g., under 21 CFR part 314, subpart H, § 314.520 “Approval with restrictions to
assure safe use”).
A boxed warning can also he used in other situations to highlight warning
information that is especially important to the prescriher. Information included in
the WARNINGS AND PRECAUTIONS and CONTRAINDICATIONS sections
should therefore be evaluated to determine whether it should also be placed in a
boxed warning. (FDA 9)
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Although the FDA has not made the labeling requirements for black box warnings a
mandatory part o f DTCA yet, many prescription ads use the black borders in their layout.
The design o f the Lipitor ads, however, features all o f the text on the back o f the productclaim ads in black boxes (see Figure 11). With this format, all o f the side effects and
risks are treated equally and highlighted without discretion in the discourse. Therefore,
nothing truly stands out or is made relevant to patients and doctors because they become
accustomed to seeing everything in black borders. Not only does this lack o f connection
to serious warnings prove more time consuming for busy physicians who must search
through the text for meaningful data, but it also could prove dangerous to the health of
confused patients.

Figure 11. Reverse Side o f Advertisement for Lipitor - Dec 2007
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Corning back to the purpose o f our analysis o f prescription D TCA ’s situated meaning
as compared to the situated meaning o f historical patent DTCA, we can see that there are
a few differences between the two discourses. Unfortunately, these differences do not
support the pharmaceutical companies’ claims that they are using DTCA to educate
consumers about conditions or diseases. Instead, any significant changes in the ads - as
compared to the historical ads - typically result from factors which are essentially beyond
the companies’ control and reflect how businesses react to potential legal issues that
impact drug advertising. For instance, prescription DTCA’s frequent use o f modal verbs
to soften their claims about medications and advisory statements to consult physicians are
elements we did not see in patent DTCA. However, the drug companies use these new
elements as a way to avoid sanctions by the FDA versus as a tool for educating readers.
We also saw how the FDA laws have made the addition o f side effect and risk listings a
part o f prescription DTCA, but the pharmaceutical companies only comply with the
necessary information that focuses on the advertised drug. The companies rarely offer
any additional information that does not directly relate to the medication. As a result, the
reverse side o f product-claim ads hardly encourages close reading, and consumers often
find it difficult to glean any substantial information about a disease or condition from the
DTCA.
Therefore, in terms o f situated meaning, we cannot ignore the strong similarities
which exist between the two discourses. Both patent and prescription DTCA tend to use
language in a m otif that builds connections between potential common health conditions
and the consumers. The main difference is that in the patent DTCA, like Lydia
Pinkham’s Vegetable Compound and Peruna, just about any symptom could be included
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in the ads. Although, today the FDA keeps strict controls on the pharmaceutical
companies which forces drug companies to be more specific in the listed indications, the
prescription DTCA still evinces a desire to use fear as a way to make the ads relevant to
readers.
In addition, both patent DTCA and prescription DTCA consistently structure the text
o f ads towards a theme that implies a condition is degrading the quality o f consumers’
lives and only the advertised drugs can help. In that regard, very little has changed
between the directives in Lydia Pinkham ’s Vegetable Compound ads that “No other
medicine has such a track record o f cures...” and “Refuse to buy any substitute”
(Pinkham 1906) and Dr. Jarvik’s assertion in the Lipitor ads that any generic drug would
not be acceptable. Both discourses also tend to use syllogisms to help normalize or
medicalize the prototypical simulations the public uses to make decisions.
Finally, the text o f both discourses contains elements which make other options
irrelevant even if they could be effective to a given condition. In the past, the connection
between patient and physician was broken because patent DTCA had the freedom to
eliminate the interaction. With FDA requirements as to wording, prescription DTCA
does not have this same tfeedom, but chooses instead to break the connection to future
decisions about generic drugs and lifestyle changes.
Overall, in terms o f situated meaning, prescription DTCA appears to approach the
building task o f connections in a way that does not clearly indicate a genuine desire to
enact any other situated meaning than that o f advertising. To ensure we are giving the
discourse a fair examination, however, we will look at the ads through one final building
task - that o f sign systems and knowledge - in the next chapter.
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CHAPTER 4

SIGN SYSTEMS AND KNOWLEDGE
Thus far, we have seen how the building blocks o f a discourse like pharmaceutical
advertising shape meaning through identity and connections. However, these elements
are far from being the only means o f creating a context for a situation. In fact, authors
must work continuously to reinforce the “reality” (Gee 11) which is their ultimate goal
for a particular discourse. A corpus will exhibit these other means o f accomplishing a
desired effect, or the “who” doing “what,” through many building tasks. Besides the
tasks o f identity and connections that we discussed in earlier chapters, a discourse will
also tend to use visual images and text which make specific sign systems and knowledge
important to a situation in an effort to foreground particular elements (Gee 13).
This chapter explores our corpus o f advertising for this building task o f sign systems
and knowledge, again applying G ee’s criteria for the task to the patent advertisements for
Lydia Pinkham’s Vegetable Compound and Peruna and the prescription DTCA for
Nexium and Lipitor. An analysis o f both discourses in this manner will give us another
lens through which to view the similarities or differences between the two advertising
formats. Ultimately, this study will determine if enough differenee exists in situated
meaning to support pharmaceutical company assertions that they not only sell medicines
but also educate readers to shape them into well-informed patients.
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Once more, Gee offers us assistance in doing a discourse analysis through his
research questions for each building task. For the purpose o f sign systems and
knowledge, our prompts for exploration include:
1) W hat sign systems are relevant (or irrelevant) in the situation (e.g. speech,
writing, images, and gestures)? How are they made relevant (and irrelevant), and
in what ways?
2) What systems o f knowledge and ways o f knowing are relevant (or irrelevant)
in the situation? How are they made relevant (and irrelevant), and in what ways?
3) What social languages are relevant (or irrelevant) in the situation? How are
they made relevant (and irrelevant), and in what ways? (112-113)
The term “sign systems” may seem abstract at first, but this concept simply represents
the various communicative tools we have at our disposal with which to convey an idea to
others. Gee, in fact, strongly emphasizes that language is only one o f many sign systems
and that we tend to pull graphs, images, equations, and other non-language elements from
our discursive toolbox in a way that helps us create situated meaning in a social
interaction. More importantly, the way we structure and position these sign systems, and
how we use them to make knowledge or belief claims, undeniably privileges - or values
- one system over another (Gee 101).
More importantly, sign systems are the essential building blocks for the construction
o f various types o f knowledge. Therefore, we can use certain sign systems, either alone
or in combination, to privilege a specific form o f knowledge in a discourse. Gee points
out, for instance, that Native Americans, or “real Indians,” transmit their “cultural
knowledge” through sign systems that are difficult for “non-Indians” to imitate (25). The
gestures and speech patterns o f “Indians” make a claim to cultural knowledge that closes
a discourse to outsiders. Other forms o f knowledge tend to have their own sign systems
and are often privileged in pharmaceutical advertising.
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Social knowledge is the term this thesis will use for the common or ordinary
knowledge that is transmitted on an affective level through interaction with others in a
group. This social knowledge usually takes the form o f “everyday language” (Gee 101)
and is mediated through the experiences o f those around us. Social knowledge is difficult
to quantify because it often privileges human emotions over factual data and relies on the
recipient’s receiving and responding to stimuli. For this reason, Bertrand Russell referred
to this type o f knowledge as “knowledge by acquaintance” or “experient knowledge”
because it is conveyed through direct awareness.. .of the thoughts, feelings and desires”
(qtd in Hayner 423) o f others. As this chapter will show, the testimonials in
pharmaceutical advertising are particularly effective in constructing social knowledge
because for the recipient “social knowledge amounts to some capacity for cheaterdetection, and some information about the reliability o f different types o f people” (Kusch
11). Therefore, social knowledge can be privileged if readers o f an ad believe a
spokesperson or image to be genuine.
In addition to social knowledge, pharmaceutical advertising often uses sign systems
that privilege or make claims to scientific and judicial knowledge. These types of
knowledge tend to be - or at least appear to be - more fact-based and positivist, although
both usually take advantage o f rhetorical appeals to persuade an audience. Claims to
scientific knowledge would depend on the presence o f observable data while judicial
knowledge would be privileged with the use o f rules and standards for right and wrong.
As we will see in this chapter, however, scientific and judicial knowledge, when used in
advertising with outsiders (e.g. average consumers), effectively closes the discourse just
as “non-Indians” are excluded from “Indian” discourse.
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In order to further clarify the building task o f sign systems and knowledge, Gee
returns once more to the example o f a business meeting that this thesis included in
chapters 2 and 3. In the situated meaning o f the business meeting, we said the person
leading the meeting behaves and speaks in a particular way to gain recognition as the
chair, thus the identity o f the chair is situated in the discourse o f the meeting. At the
same time, the person leading the meeting would use specific language to make
connections between what is said in the meeting to a time outside o f the meeting.
Furthermore, the meeting chairperson would also ensure that he/she uses a social
language and gestures (sign systems) which privilege the business environment - or
corporate knowledge - versus using sign systems which would be more appropriate for
“everyday” conversation (Gee 101). For example, we would typically speak to peers and
subordinates in a much more professional manner, so we would not use the same
language, body movements, etc., in a business meeting that we would use when speaking
to close friends. We ean also think o f sign systems as being the outcome o f how well we
understand the nuances o f our rhetorical purpose.
In our study o f pharmaceutical advertising, we can find many types o f sign systems
whieh imply a type o f knowledge, but this chapter will pay particular attention to the
various non-language sign systems, such as images and ad design, in the discourse. In
addition, the social languages used throughout the unregulated patent DTCA and today’s
FDA-monitored preseription DTCA will equally inform our determination o f drug
marketing’s situated meaning. Ultimately, this chapter will show how these sign systems
work together to make eertain types o f knowledge - specifically social, scientific, and
judicial - relevant (or irrelevant) in the discourse. It is important to mention at this point
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that some o f the elements which will be discussed in this chapter as communicative signs
were also mentioned in the previous chapters as part o f building identity or connections.
This versatility is to be expected and occurs because, as Gee often notes, the components
o f a discourse usually function as multiple tasks within a single situation. So, a particular
element o f an ad, such as a photograph, can easily assist an author in building identity,
connection, and, as we will see in this chapter, knowledge.
Images played a large role as a sign system in the patent advertising published prior
to FDA regulation. As we saw in chapter 2, the images helped establish identity for the
drug maker, but, in terms o f communicative systems, they also served as instantrecognition symbols for anyone who saw the ads. From only a quick glance, a reader
knew instantly which sectors o f the population the drug maker was targeting. Lydia
Pinkham’s Vegetable Compound ads, for example, usually featured the familiar face of
the maker or a female who could be a sister o f sorts to the reader. These images typically
took up a large portion - in some cases over half the advertising space - o f the ads, so it
is evident that the Pinkham company saw these non-language sign systems as being equal
in importance to the text in making a knowledge claim to potential customers. Since the
drug was touted as being a wonder drug for “female weakness” (Pinkham, 1883), the
images would certainly have captured the attention o f women readers. Moreover, the
visual aspect added weight and reinforcement to the many testimonials in the language o f
the ads.
Not surprisingly. Dr. S. B. Hartman’s company also positioned images in prominent
areas o f its Peruna ads to quickly convey the type o f people who took the drug and to
support the claims made in the textual component. More importantly, though, the Peruna
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ads used graphies whieh demonstrated the eompany’s belief that a diverse portion of
soeiety should be taking the medieation. Like the Pinkham ads, the Peruna ads
eonsistently divided the allotted spaee equally between text and drawings, although the
Peruna ads ineluded images o f men, women, and entire families rather than foeusing on
just one démographie. One ad, in partieular, used a smaller drawing o f a nun inset on a
much larger image o f the orphanage to which she was assigned. The overall drawing
easily took up over half o f the ad and effeetively made the elaim that major institutions,
such as “St. Vincent’s Orphan Asylum” (Peruna, 1899) were buying and using Peruna.
The layout (e.g. font type/size, borders, etc.) o f the ads is itself a sign system beeause it
telegraphs the soeial knowledge that the authors want the audienee to have after reading
the discourse. According to James Harvey Young, this aspect o f the patent DTCA was
always a premeditated faetor beeause “Distinetive type indueed a feeling o f
familiarity.. .[just as] pietorial symbols served the same function” (167). In the case o f
Lydia Pinkham’s Vegetable Compound, the ads used repetitive lines printed in various
fonts that appeared in random plaees within an ad and eontinued into other ads for the
drug. For instanee, one ad in 1879 (see Figure 12) used signifieantly different font from
that o f the surrounding text to share the overall message o f the ad in a few seattered lines.
This larger, bolder font loudly tells the reader that “MRS. LYDIA E. PINKHAM” is the
maker and that the drug is for “Female Complaints” and is a “METHOD OF CURE”
(Pinkham, 1879). Other Pinkham ads used bolding, underlining, or fnlly borders to
eapture these same thoughts in a few key areas o f the text, sueh as in Lydia Pinkham’s
name or the allusion to female illnesses.
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Figure 12. Advertisement for Lydia Pinkham’s Vegetable Compound - 1879

The Peruna ads mirrored the layout used in other patent DTCA, like Pinkham’s,
because the Hartman company used different font sizes and types to help distinguish the
drug and the people taking it. Most often, the Peruna ads employed a bolded headline
like “PERUNA PROTECTS THE FAMILY. Coughs and Colds. Grip and Catarrh” (see
Figure 13) at the top o f the advertising space to encapsulate the most important
information. This formatting was a way for the Hartman company to impart social
k n o w led g e b ecau se, i f the consum ers w ere to read o n ly the aforem entioned text, th ey

would still walk away with a coherent message about the patent medicine.
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Figure 13. Advertisement for Peruna - 1901

The patent drug makers used the imagery and layout o f the ads to appeal to the
emotions o f consumers and to thus privilege social knowledge about medicine and
illness. O f course, to fully develop a message, the non-language aspects o f the patent
DTCA worked in combination with the social languages in the discourse. According to
Gee, multiple social languages or voices in a discourse are common and have the
potential to make a corpus “heteroglossic.. .[or] ‘double-voiced’” (37). We can see this
mix of social languages in patent DTCA because it tended to be composed of two
different voices. The first voice was the authoritative, pseudo-scientific language we
might expect to hear from a patent drug company trying to work its way into the
discourse o f the medical profession. The words o f the third-person narrators in the Lydia
Pinkham Vegetable Compound and Peruna ads, for example, were authoritative because
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they set the tone that both eompanies knew what was best for not only siek eonsumers but
also for physicians. Thus, the ads placed emphasis on seientifie knowledge in lines such
as “For all Weaknesses o f the generative organs o f either sex, it is seeond to no remedy
that has ever been before the public” (Pinkham, 1883) and “ ...a certain, absolute eure for
eatarrh is a publie good” (Peruna, 1899).
The words in the ads also typified the medical terminology which was probably
intrinsic to insiders o f the medieal profession but often unfamiliar, yet persuasive, to the
public. The ads for Lydia Pinkham’s Vegetable Compound, for example, often stated the
drug was good for “Falling o f the Uterus, Leucorrhoea, Bearing Down Feeling...”
(Pinkham, 1879) without speeifically explaining the terms or the stated indieations. The
ads for Peruna from 1885 to 1901 overwhelmingly favored the term “catarrh” (Peruna,
1899) and used it for just about any eondition imaginable. In fact, in Dr. Flartman’s
opinion catarrh could mean anything from appendieitis to mumps to female eomplaints to
“whatever ails you” (Adams 13). The abundant use o f strange, medieal-sounding terms
with no el ear definition - but with the appearance o f seientifie knowledge - was therefore
one o f the most criticized features o f patent medicine advertising. Samuel Hopkins
Adams seathingly reprimanded the patent medieines or “subtle poisons” (32) for
persistently using terms not readily known to the seientifically ignorant, yet hopeful,
eonsumer.
The seeond voiee we hear in patent DTCA is that o f the average person engaged in
everyday social conversation. The drug makers relied heavily on testimonials to help
them sell the patent medicines because the words o f people who could be perceived as a
reader’s family or friend were extremely eonvineing. Therefore, the language the ads
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used to create this familiarity had to be simple and homespun. One ad for Lydia
Pinkham’s Vegetable Compound, for instance, featured the testimonial o f a young
woman who stated, “It was highly recommended to me by a friend. Now I feel like a
different girl; no more aches and pains. I am praising it to every one” (Pinkham, 1896).
Employing this same type o f social language, a testimonial in an ad for Peruna declares,
“I feel like a different person already. A number o f my friends have used it, and they
think it is a wonderful remedy” (Peruna, 1886).
The construction o f this social language, with its direct sentence structures and easy
vocabulary, shows that the drug makers wanted the discourse to be conversational. As
mentioned earlier, this type of language is a good way to transmit social knowledge
because the participants feel as though they share experiences within a relationship. O f
course, many authors (Adams; Young; Bok) have questioned whether the testimonials
were really written by consumers or were fabrications o f the patent drug companies, but
consumers seemed to react favorably in either case. In terms o f privileging a particular
social language, patent DTCA divided the advertising space equally between the two
different sign systems, so we can see that they did not necessarily privilege one above the
other. Instead, the patent drug makers preferred to keep the two languages working in
tandem to make an assertion to the reader.
An important point to note, however, is that the patent DTCA did not privilege
scientific knowledge or value any language or information in the ads that was not directly
related to the advertised drug. For example, no patent advertising ever mentioned the
causes for a condition or the alternative choices available for alleviating an illness.
Instead, the patent DTCA included text in every ad that directed readers to write to the
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drug maker for more information about healthcare issues rather than waste advertising
space to any educational material. The Pinkham company, for instance, had its “Guide to
Health” available for requestors while the Hartman company offered a booklet entitled
“Ills o f Life.” These information pamphlets, however, often turned out be nothing more
than additional advertising for the patent medications (Adams; Young).
As we saw earlier in this thesis, patent DTCA provides us with a good example o f a
discourse whose primary situated meaning was the advertisement o f a product to the
public. In the building task o f sign systems and knowledge, the patent DTCA once again
supported this “who doing what” o f advertising in a number o f ways. The non-language
sign systems - the images and format - facilitated the social knowledge about the drug
that the patent medicine companies hoped to convey. The social languages, also key sign
systems, in the text o f the ads allowed the audience to hear both the voice of a
knowledgeable “medical” professional and the familiar voice inherent in everyday
interaction with friends. These sign systems were intensely focused on the product and
combined to make knowledge claims about the patent medicines which would help
increase overall sales o f the drug.
With our awareness of patent DTCA’s situated meaning, we can now analyze in
comparison today’s prescription DTCA, also examining its use o f sign systems and
knowledge as a building task. As in previous chapters, our focus will include similarities,
but will ultimately search for any key differences the prescription DTCA have from the
patent DTCA. Significant differences we find in the use o f sign systems and knowledge
would help support pharmaceutical company assertions that they are doing much more
than advertising a drug.
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As a communicative tool, images have certainly retained their value to the discourse
o f drug makers. In fact, the modem ads have access to techniques, like color
photography and digitally generated graphics, that patent medicine manufacturers could
only have imagined. Therefore, the visual aspects o f prescription DTCA today are eye
catching with their tme-to-life representations o f people and products. If we were to look
solely at the images in the ads for Nexium, for example, we would always see the pill - in
its lifelike purple and gold form - that the AstraZeneca company is featuring. The image
o f the pill silently makes the claim that only this particular drug is going to help heal acid
reflux, so the consumers need to know exactly what the pill looks like when they request
it from their doctor.
The Nexium ads also use photographs o f everyday people who look healthy and
happy, but, as we soon discover, are unaware o f their problems. The people featured in
the color photographs are fathers, teachers, grandfathers, etc., and all look toward the
camera with smiles and robust demeanors. In one Nexium ad, for instance, a father is
laughing with his children as they all play in a tree house together. At first glance, the
reader gets the impression that this is a normal family doing everyday activities. But, the
captions inset on the photos actually disprivilege the happy scenario in the photo with
warnings about the impending illness that is ready to strike down the father. Even though
the photographs take up over half o f the advertising space, the captions take precedence
with statements such as “Knows they have homework. Knows they have chores. Knows
their favorite hiding place. Doesn’t Know acid reflux may be damaging his esophagus”
(Nexium, Sep 2006). Suddenly, what the readers initially thought they knew turns out to
be incorrect.
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The ads for Lipitor use color photographs in ways that not only build social
knowledge but also make vague claims to scientific knowledge in order to add prestige to
the captions. At the top of every ad, the ubiquitous representative o f Lipitor - Dr. Robert
Jarvik - gazes calmly at the reader with a reassuring smile. He wears a white lab coat
and a blue-plaid shirt whose colors exactly match the colors in Pfizer’s blue logo that
appears at the bottom o f the ads. If we look closely at the image, we also see other
people wearing white coats in the background. In fact. Dr. Jarvik and these other people
appear to be standing in a laboratory o f some kind (see Figure 14).
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Figure 14. Advertisement for Lipitor - Dec 2007

Without even reading the text, the reader can quickly look at the photograph and
conclude that this is a group of medical professionals engaged in scientific endeavors.
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This assumption can lead readers to believe the group will share reliable, scientific
knowledge with them. The captions inset onto the photograph then use another type o f
non-language sign system - numerical percentages - to further support and privilege this
idea. For example. Dr. Jarvik him self assures the reader that “Lipitor lowers bad
cholesterol 39-60%...” (Lipitor, Dec 2007). Statistics such as these, although not fully
explained in the ads, can be very persuasive to an audience which is uneducated about the
medical studies.
Other non-language sign systems in the prescription DTCA are equally reminiscent of
the patent DTCA because the ads depend on formatting to privilege a message and make
a knowledge claim about the drugs. AstraZeneca is especially creative at doing this in its
layout for the Nexium ads. All we have to do is look at the colors used in the design of
the ads to see that they foreground a correlation to the “little purple pill” (Nexium, Jun
2007). Every ad for Nexium uses a purple background to the textual fields o f the ads. In
addition, most o f these ads separate the textual element from the visual component with a
small gold line. Each o f the captions for the image at the top o f the ads is also underlined
in gold. In combination, these colors - purple and gold - call to mind the exact drug
Pfizer is marketing in the situation. In effect, looking at the ad’s visual cues in their
entirety is the same as looking at one o f the Nexium pills.
Moreover, the Nexium ads echo a technique we saw in the patent DTCA for Lydia
Pinkham’s Vegetable Compound by strategically placing bolded lines of text - again in
AstraZeneca’s trademark purple - in random positions throughout the advertising space.
These lines are in a larger font size than the surrounding text, so they quickly stand out to
the reader. One Nexium ad (see Figure 15), in particular, demonstrates how scattering
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key lines o f text and using various non-language sign systems can effectively come
together to build social knowledge in prescription DTCA. First, this ad’s entire
background is a single, color photograph o f a woman wearing a red scarf. The red scarf
is carefully positioned in the image to represent the woman’s irritated esophagus. We
soon leam this is true because a font - in a different type from that o f the rest o f the ad is superimposed on the length o f the scarf claiming, “Behind this scarf acid could be
burning the lining o f her esophagus” (Nexium, Jul 2006). To reinforce our knowledge as
to how dangerous acid reflux can be, the scarf is knotted around the woman’s neck. As is
the typical color scheme for Nexium ads, the woman is wearing a light purple shirt and is
standing against a dark purple backdrop. The graphic o f the purple and gold Nexium
capsule is positioned close to the woman’s heart.

Npiff'tnrt.

Figure 15. Advertisement for Nexium - Jul 2006
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This Nexium ad then employs the technique o f formatting certain lines in a different
font type/size in a way that communicates a coherent message even if readers were to
only read those lines. As shown in Figure 15, the resulting message from the scattered
lines in this particular ad is:
IT’S DIFFERENT FOR PEOPLE WITH ACID REFLUX DISEASE. Because
beneath the heartburn, something more could be brewing. Acid reflux disease can
damage your esophagus. NEXIUM heals the damage. Talk with your doctor
about Nexium. FOR A FREE TRIAL OFFER, Visit PURPLEPILL.COM....
(Nexium, Jul 2006).
The ad does mention a medical condition, but the focus o f these carefully placed lines is
directly on the prescription drug that AstraZeneca is advertising.
An example o f a Lipitor ad which effectively ties together several non-language sign
systems to build social and scientific knowledge is shown in Figure 16. The photograph
and graphics o f this ad dominate over half o f the advertising space. The photograph
shows Dr. Jarvik in casual street clothes this time versus his usual white lab coat. The
caption under the image privileges this apparel as it states Dr. Jarvik is “Inventor o f the
Jarvik Artificial Heart and Lipitor User” (Lipitor, Nov 2007). Thus, the readers now
know that Dr. Jarvik is not only a medical professional but also one o f the audience
members - an insider who shares their social knowledge.
In the photograph. Dr. Jarvik stands in front o f a dark background in which we now
see a much-larger, realistic scan o f a human skull and brain. Subtly, the image makes the
claim that Dr. Jarvik also possesses scientific knowledge because he can discuss aspects
o f the brain. To the side o f the brain scan and Dr. Jarvik, the ad also privileges a
numerical statistic stating, “ .. .Lipitor reduces risk o f stroke by 48%” (Lipitor 2007).
Directly under the photograph, this Lipitor ad shows a blue field which coincides with the
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colors Pfizer uses for their logo. The familiar blue font is then carried over into the
remaining textual component o f the ad for continuity. As with the Nexium ads, the
Lipitor ads use these non-language sign systems to privilege the medication, and any
stated symptoms o f a health condition are usually re-routed back to the drug.
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Figure 16. Advertisement for Lipitor - Nov 2007

Short quizzes, another innovative method for communication, also appear in
prescription DTCA to help build a perception o f scientific knowledge about a drug.
Nexium ads, for example, sometimes use a three-question, true/false quiz for readers to
answer. The questions include such statements as “If I have heartburn, I shouldn’t worry
about it” (Nexium, Sep 2006) and are portrayed as attempts to dispel myths about acid
reflux. O f eourse, the answer to the question previously mentioned is “False” (Nexium,
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Sep 2006), so the non-language sign systems again bring the reader’s attention right baek
to the advertised drug. The quizzes in preseription DTCA are unique elements that invite
eonsumers to read themselves into the ads as they answer the questions.
The language sign systems in preseription DTCA also have a great deal in eommon
with the patent DTCA beeause we again hear multiple voiees in the diseourse just as we
did in the historieal ads. Whereas the patent DTCA showed two distinet soeial languages
working together, however, the preseription DTCA shows a tendeney to use three
languages which ironically do not work as well in combination. First, prescription
DTCA mirrors patent DTCA in that it often speaks to the readers in the soeial language
o f everyday conversation. The ads for Nexium, for example, often use humor in the
short, declarative sentences which form the captions for the visual elements. One ad
demonstrates this when it alludes to an old, familiar joke as it states, “Knows no dog has
ever eaten any homework” (Nexium, Jun 2007). Other preseription DTCA continues to
use testimonials in the form o f well-known spokespersons, like Lipitor’s Dr. Jarvik, who
talk to the audience in simple-to-understand language and appear to take the readers into
their confidence. These conversations with the readers are not very different from the
interactions we usually have with friends or family.
Next, preseription DTCA uses the authoritative voiee usually reserved for the
seientifie language o f medieal professionals in a way that is similar to the language in
patent DTCA, although the tone in today’s advertising appears to be more tentative in its
approach at times. Just as a physician would first diagnose a problem and then prescribe
treatment for it, the preseription DTCA tells the readers what their health problem
probably is and what the treatment - the advertised drug - should be. The Nexium ads.
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for instance, begin with bolded headlines such as “Even if you’re treating your heartburn,
you may still have damage” (Nexium, Jun 2007) and “This condition may affect 1 in 3
people with acid reflux disease, and if left untreated, could get worse” (Nexium, Jan
2007). In participating in the language o f medical experts, prescription DTCA does
provide an explanation, o f sorts, for the indicated health condition, but the clarification
normally comes in the form of parenthetical definitions which do not fully expound on
the causes or symptoms.
Instead, the ads tend to make social knowledge more relevant than scientific
knowledge because they give one or two distinguishing features o f the stated health
concern and then return quickly to the brand name o f the drug. Nexium ads, for instance,
prefer to state, “If you suffer from acid reflux disease - persistent heartburn 2 or more
days a week, despite treatment and diet change - you could have serious damage to your
esophagus and not know it” (Nexium, Jan 2007). In this statement, acid reflux is defined
in a parenthetical manner as stubborn heartburn even though many other symptoms are
typically present if a person genuinely has acid reflux. Pfizer’s ads for Lipitor use the
same method o f definition in the discourse, but their primary emphasis is on defining the
drug rather than the health issue. For example, Lipitor ads usually begin with the line
“LIPITOR is a prescription drug” (Lipitor, Nov 2007) and proceed to list what Lipitor’s
distinguishing features are. The ads tell readers that “It [Lipitor] is used in patients with
type 2 diabetes, and at least one other risk factor for heart disease...” (Lipitor, Dec 2007),
but do not explain what the term “heart disease” can encompass.
In addition, the ads continue the vague scientific discussion with a remedy for the
health problem. Naturally, pharmaceutical companies want to sell their products, so the
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prescription DTCA offers a cure in the form o f the advertised drugs. Nexium ads make a
claim to scientific knowledge when they state the drug “not only provides 24-hour relief
from heartburn” but also “can heal even the most severe erosions in the esophagus caused
by aeid reflux” (Nexium, Jan 2007). At the same time, this knowledge is made less
relevant when the language in the ads significantly modulates the phrasing with
qualifying words, sueh as “if,” “may,” and “could” that conflict with the confident timbre
we would expect o f a licensed medical professional. The ads also include the reminder
that “only a doctor can determine if you have this condition” (Nexium, Sep 2006), but
this statement is a requirement o f the FDA and establishes the third voice - that o f legal
professionals - in prescription DTCA.
Pharmaceutical companies predominately use language to build judicial knowledge in
their DTCA in a way that was unheard o f in historical, patent medicine advertising.
Ironically, this third voice o f prescription DTCA has evolved through FDA laws
pertaining to “product-claim” ads. These ads allow the drug manufacturer to focus on
specific prescription medications and the situations which would indicate the need for the
drugs, but in presenting a drug to the public, the drug company must follow a set o f rules
the FDA outlines. For example, a produet-elaim ad “must present a ‘fair balance’ o f
benefit and risk information” and “if they are in print, contain a ‘brief summary’ o f a
drug’s side effects, indications and effectiveness” (NIHCM 14). Interestingly, these FDA
rules inadvertently set up a unique, and often eonflieting, combination o f marketing and
legal genres for the prescription DTCA.
In fact, the juxtaposition o f soeial languages in produet-elaim DTCA establishes a
context in which the consumers receive information in a discordant mixture.
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Furthermore, when the building task o f “sign systems and knowledge” is used to analyze
the ads, an indication o f how “various ways o f knowing” (Gee 112) can affect meaning
and value becomes evident. For example, consumers reading the front page o f a Nexium
or Lipitor ad will hear the voice which tells them that the advertised drug is safe and
indicated for the stated condition. However, since these product-claim ads are allowed to
mention both a medicine and a medical condition, AstraZeneca and Pfizer must detail all
o f the FDA-mandated information, such as safety considerations and side effects, on the
reverse or opposite page. This cautionary information develops from legal precedents in
most cases, so the language sounds legislative in nature, is often difficult for the
layperson to decipher, and ultimately seeks to avoid future lawsuits. The language o f
lawyers comes through in the densely packed text on the reverse side o f Nexium ads, for
instance, in a sea o f terms that would understandably be impossible for average
consumers to decipher:
Symptomatic response to therapy with NEXIUM does not preclude the presence
of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric
corpus biopsies from patients treated long-term with omeprazole, o f which
NEXIUM is an enantiomer. ..Esomeprazole is extensively metabolized in the liver
by CYP2C19 and CYP3A4. In vitro and in vivo studies have shown that
esomeprazole is not likely to inhibit CYPs, 1A2, 2A6, 2C9, 2D6, 2E1, AND
3A 4.... (Nexium, Sep 2006)
Thus, the reverse side o f the ad issues a complex warning o f serious effects o f the drug
while the front side o f the ad promotes the drug as having “a low occurrence o f side
effects, which may include headache, diarrhea, and abdominal pain” (Nexium, Sep 2006).
Admittedly, the Lipitor ads do a slightly better job than the Nexium ads of
interpreting the legal language for consumers and speaking in a more natural voice, but
the overall result is identical. For example, the front side o f Lipitor ads tries to allay the
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fears o f potential users with the statement “If you take LIPITOR, tell your doctor if you
feel any new muscle pain or weakness. This eould be a sign o f rare but serious muscle
side effects” (Lipitor, Dec 2007). This claim that negative effeets hardly ever happen is
encouraging to readers, but the reverse side o f the ad complicates the knowledge by
stating the “musele problem s.. .can lead to kidney problems, ineluding kidney
failure.. .Your ehanee for musele problems is higher if you take eertain other medieines
with LIPITOR” (Lipitor, Dee 2007). Suddenly, the musele problems take on a greater
significance for consumers, and the ad never explains what other medications might
cause these life-threatening issues in combination with the advertised drug.
The two different intentions in the languages - encouraging versus warning - have
separate and distinet situated meanings o f their own and thus affect the knowledge the
eonsumer derives from the ads. Gee points this out in his own analysis o f two soeial
languages he observed on the label o f an aspirin bottle:
The first speaks with a lawyerly voiee {who) responding to specific potential legal
problems and court eases {what)\ the seeond speaks with the official voiee o f a
earing, but authoritatively knowledgeable company {who) trying to protect and
advise people, especially women and children, while still stressing that aspirin is
not particularly special or dangerous compared with drugs in general {what). O f
eourse, the seeond who-doing-what sits in some tension with the first. (37)
This eonfiiet between the languages —and the forms of knowledge - contributes to
the reason why very few eonsumers actually take the time to fully read the text on the
reverse side o f the preseription DTCA. When faced with a choice between the soeial
knowledge that a drug offers hope for a better quality of life and the judicial knowledge
enacted through confusing language that acts as a disclaimer and strives to ward off legal
problems, readers naturally gravitate to the former mode o f communication. Studies have
indicated that the complex wording o f the legal jargon deters eonsumers from reading the
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information in most cases (Murray et al, 513). The prescription DTCA appears to
anticipate this action and relies on repeated imperatives to see a doctor for more
information or training.
Therefore, prescription DTCA constantly repeats that consumers should see their
doctors for an explanation o f the language in the ads or - as patent DTCA once did - asks
consumers to send away for a free pamphlet from the pharmaceutical company. This
method o f building knowledge works against the idea that the companies might use the
ads to provide education about a disease or condition. In fact, both the non-language and
language sign systems in prescription DTCA indicate that only the advertised drug is
truly privileged in the discourse, and even most exhortations to talk to a doctor are in the
context o f asking for the drug. In their defense, pharmaceutical companies assert they
refer readers to a physician for advice in order to better educate the public, but as David
R. Hall found when he analyzed medical leaflets, “frequent exhortations to ‘see your
doctor’ actually militates against the effectiveness and usefulness o f these consumer
product” documents (273).
Overall, in comparing prescription DTCA’s situated meaning to that o f patent DTCA
for the building task o f sign systems and knowledge, the communicative signs of
prescription DTCA do not exhibit strong differences which would validate the
pharmaceutical companies’ assertions that the product-claim ads are educational material
for the public. In both patent and prescription DTCA, the images, statistics, and soeial
languages on the front side o f the ads work together to build prestige for and social
knowledge o f the advertised drug. At the same time, the language on the reverse side o f
today’s ads - albeit a mandate from the FDA - privileges a voice that works in opposition
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to the other sign systems. In fact, one has to wonder if the pharmaceutical company
would even include this information if it were not directed in FDA guidelines because the
density o f the material detracts from the desired goal o f marketing a product.
Moreover, when readers want to gain actual scientific knowledge about a disease or
condition, the tiny print at the bottom o f the ad does not offer much assistance. Instead,
physicians are expected to know everything about all prescription drugs because they
serve under the learned intermediary doctrine (LID) which “places the responsibility
solely on healthcare professionals to ensure that patient-consumers are adequately
warned, and thereby shields manufacturers from failure-to-wam suits” (Ronald, 288).
Thus, the effect the sign systems have on the relationship between doctors and patients
and their ways o f knowing about a drug is exactly what has created considerable
controversy today.
As this thesis has explained in previous chapters, however, we must pull together the
various building tasks that function within a discourse in a comprehensive manner in
order to validate an analysis of situated meaning. The next chapter will accomplish that
goal by revisiting the building tasks o f identity, connection, and sign systems and
knowledge as well as reach a conclusion about the nature o f “who doing what” in
pharmaceutical DTCA.
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CHAPTER 5

MAKING A VALID CONCLUSION
Over time, people interacting within a community or particular activity will establish
a way o f speaking and writing which has special meaning within the context o f the group.
Any new members to the group will either have to adopt these same ways of
communicating or risk being ostracized from the others. This common way o f speaking
or writing within the group helps members form attachments and gain acceptance as
insiders with the others. Therefore, the discourse used within the group will demonstrate
a specific situated meaning or what Gee calls the “who doing what” (22-23) to convey
ideas and messages. Gee further explains that:
The key to Discourses is “recognition.” If you put language, action, interaction,
values, beliefs, symbols, objects, tools, and places together in such a way that
others recognize you as a particular type o f who (identity) engaged in a particular
type o f what (activity), here-and-now, then you have pulled o ff a Discourse (and
thereby continued it through history, if only for a while longer). (27)
It follows, then, that when the insiders o f a community want to make changes to their
situated meaning, the discourse again should evince signifieant markers that show this
desire for change to be true. Furthermore, the only way to genuinely know if a situated
m ean in g has ch anged is to carefu lly an alyze past ex am p les o f the d iscou rse in

comparison with new artifacts, examining both for the ways in which they build meaning.
This comparison is necessary because “sometimes what we build is quite similar to what
we have built before; sometimes it is not” (Gee 10).
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The specific activity o f advertising medications to the public is, and has been for a
long while now, a subject o f much debate in our society. As we saw in chapter 1, the
fight to regulate what drug makers can say to the public started in 1905 with Samuel
Hopkins Adams’s Great American Fraud articles and continues today. Critics, past and
present, of DTCA argue that the discourse is merely the language o f marketers whose
only concern is selling a product. The pharmaceutical companies today, however, assert
that the new prescription DTCA has elements which not only talk about a brand-name
drug they wish to sell but also are intrinsically educational about diseases and conditions.
Like it or not, consumers and their physicians have always been the targets of
medicine advertising and therefore have the ultimate responsibility in deciding which
advertised drugs are warranted. As early as 1800, Young points out that an editor stated
about patent DTCA, “The vendors o f patent m edicines.. .in the U.S. are fattening on the
weaknesses and folly o f a deluded public” (32). The advertising continues to this day, so
the constant barrage o f multi-media print and television advertising forces consumers to
make judgments about the content and claims. The consumer, unfortunately, is thus
under considerable pressure to distinguish between selling technique and factual
information. Therefore, the audience for drug marketing would benefit greatly from a
close reading o f the ads to better understand the intentions exhibited in the discourse.
The challenge for this thesis was to determine if the pharmaceutical companies’
claims - that the situated meaning in their advertising was different from that o f earlier
drug advertising - is accurate. To accomplish this goal, the study had to include
examples o f drug advertising from the past because older artifacts o f a corpus are
essential in comparing the discourse across time. Since the non-regulated patent DTCA
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theoretically falls within the same discourse community as the prescription DTCA, this
study went all the way back to the advertising that Adams was so contemptuous o f in his
1905 critiques. This study thus selected two samples - Lydia Pinkham’s Vegetable
Compound and Peruna - from the many artifacts o f patent DTCA available for use in this
analysis because both patent drugs sold extremely well and were mentioned by name in
Adams’s articles. These patent ads were then placed alongside two o f today’s ads for
prescription medications - Nexium and Lipitor - using Gee’s theory for examining
situated meaning as the methodology for the comparison. The next concern o f this thesis
was to ensure that the method o f analysis was valid. Once again. Gee’s theory o f
discourse analysis provides criteria which assists us in determing validity.
In fact. Gee discusses two criteria - coverage and convergence - which, if shown to
exist in an analysis, can ensure the determination o f whether a discourse’s situated
meaning is valid. Gee explains that “the validity o f the analysis will reside in how the
ideas we can generate [from one set o f artifacts] help to illuminate other data (coverage),
data that we hope will lead us to similar constructions (convergence)” (Gee 154). In
other words, unless we have these standards by which to judge a final determination, we
cannot expect any analysis to be convincing. Therefore, this chapter will explain how
this study o f patent and prescription DTCA met both the criteria o f coverage and
convergence in its effort to do a sound analysis. In addition, this chapter will make a
final assertion about the nature of prescription DTCA’s situated meaning and offer
recommendations to pharmaeeutieal eompanies in regard to their advertising.
Coverage, as Gee defines it, is the premise that “the analysis is more valid the more it
can be applied to related sorts o f data. This includes being able to make sense o f what
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has come before and after the situation being analyzed...” (114). W ith that idea in mind,
this study began its analysis o f pharmaceutical advertising with a search for artifacts that
were representative o f a corpus o f patent and prescription DTCA. The amount o f
material available for historical and current drug advertising is overwhelming to say the
least. W ith the set o f artifacts in hand, this thesis then examined the patent DTCA that
predated today’s prescription drug advertising for indications o f the construction tools or
building tasks that Gee provides in his theory o f discourse analysis. It quickly became
apparent that any o f G ee’s building tasks would have been appropriate for looking at the
pharmaceutical advertising, but this study focused on identity, connections, and sign
systems and knowledge because these methods for creating reality within the situated
meaning were most evident.
The study then employed the same analysis for the building tasks o f identity,
connections, and sign systems and knowledge to make a fair and consistent analysis of
the prescription DTCA. Although other building tasks were clearly present in
prescription DTCA, the study did not deviate from those elements used to evaluate patent
DTCA. In this way, the thesis achieved the validity marker, as Gee defines it, of
coverage and could progress to the issue o f convergence.
The premise that a corpus will tend to have the same situated meaning - who doing
what - the more the building tasks meld within and between artifacts was an extremely
important factor for this study’s overall purpose. According to Gee, “a discourse analysis
is more, rather than less, valid (i.e., ‘trustworthy’), the more the answers to the [questions
outlined in his building tasks] converge in the way they support the analysis or, put the
matter the other way round, the more the analysis offers compatible and convincing
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answers to many or all o f them” (113). Therefore, this thesis predicted that if the analysis
did not result in significant convergence o f the building tasks in patent and prescription
DTCA, the likelihood that their situated meaning was the same would be very small.
This outcome would then have supported pharmaceutical companies in their argument
that prescription DTCA has an educational role about diseases and conditions and is not
simply a marketing tool for the drugs. On the other hand, if there were considerable, or
possibly absolute, convergence between patent and prescription DTCA on the building
tasks, the prescription DTCA’s situated meaning would be identical to historical
examples o f medicine advertising and would not lend credence to the idea that
prescription DTCA is different from earlier drug advertising.
Considering the criteria o f convergence, we can see that the building tasks o f identity,
connections, and sign systems and knowledge in patent DTCA came together in a number
o f ways in the visual and textual components o f the ads to highlight a company selling a
product. First, the visual component functioned to build both identity and sign systems
and knowledge. In previous chapters, we discussed how the Pinkham and Hartman
companies carefully crafted the identity they wanted to be perceived as having in the
discussion o f healthcare through the illustrations o f people who were safely and happily
taking Lydia Pinkham’s Vegetable Compound and Peruna on a daily basis. The Pinkham
company centered its imagery on women, especially on Lydia Pinkham herself, because
the medication was supposed to be good for “female weaknesses” (Pinkham, 1883). The
illustrations o f the caring, motherly figure o f Lydia Pinkham helped solidify her authority
to speak to other women on the subject o f their medical needs. As times changed for
women, the Pinkham company also became adept at creating new images o f women, or
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“working girls” (Pinkham, 1896), in the workplace to maintain the drug m aker’s role o f
advisor to women. As for the imagery in the Peruna ads, the Hartman company went
after practically everyone in the general public, as the DTCA clearly demonstrated with
ever-changing drawings o f men, women, nuns, congressmen, and entire families. The
Hartman company clearly wanted the position o f medical expert and authority for all
consumers. Both patent drug makers, therefore, visually conveyed the image they
wanted to have with society.
But, as previously mentioned, identity for the companies was only one part o f the
value o f visual components because they worked equally well for the building task o f
sign systems and knowledge. The illustrations o f the female customers in the ads for
Lydia Pinkham’s Vegetable Compound, as non-language sign systems, communicated to
women who might not be using the drug that they too could trust the medication to be
effective. Considerable advertising space - up to half the page in most cases - was
devoted to the drawings o f average women said to be taking the drug, so the Pinkham
company obviously realized a way to fully engross a female reader who might otherwise
bypass the ads. In keeping with its identity, the Hartman company’s imagery in the
Peruna ads made the claim to consumers that a wide variety o f people believed in the
efficacy o f the medication. After all, one ad even subtly indicated that an entire
orphanage was using a steady supply (Peruna, 1899).
The layout o f the ads was another non-language sign system that greatly affected
awareness o f the patent drugs (identity) and easily merged with the task o f building
connections. In particular, randomly scattered lines o f text - in a distinctively different
font type/size than that o f surrounding lines - ran throughout the layout o f the ads for
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Lydia Pinkham’s Vegetable Compound and formed a coherent message to readers when
the lines were joined together. This sign system not only made the knowledge claim that
the drug was a “METHOD OF CURE” (Pinkham, 1879) but also helped women change
their ideas o f what should be considered normal or abnormal, one o f the common motifs
in patent DTCA. As we saw in chapter 3, the treatment o f common symptoms as a
problematic condition influenced consumers’ “prototypical simulations” (Gee 95-96) for
illness. In this case, simply being female somehow connoted a weak character that must
be treated with a chemical remedy. The Hartman company’s imagery capitalized on this
theme too, but they exhibited a layout that privileged a larger audience for its product in
an effort to also help a diverse population make the connection that certain illnesses, like
the ubiquitous “catarrah” (Peruna, 1899), were universal to all members o f society another m otif o f patent DTCA - and m ust be cured with multiple bottles o f Peruna.
The textual component o f the patent DTCA complemented the messages o f the visual
element and demonstrated convergence in its overwhelming compatibility in all three
building tasks o f identity, connections, and sign systems and knowledge. In terms o f
identity, we saw how the Pinkham company avoided direct “I” messages that might
divert attention away from the manufacturer’s authority in discussions o f the drug. Only
the testimonials, for example, for Lydia Pinkham’s Vegetable Compound and Peruna
directly addressed the readers; otherwise the ads were narrated in a third-person,
authoritative voice. This detached tone allowed the patent drug makers to escape some
accountability and preserve the perception that the patent drug makers were every bit as
professional about medicine as the regular physicians.
The text o f patent DTCA then continued the separation from medical doctors as it
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tried to break connections and assume multiple social languages to effect knowledge. For
example, we discovered that Peruna ads were very straightforward in their attempts to
make physicians irrelevant with persistent assertions that nothing but the drug was
effective. This was a common theme in patent DTCA as “throughout history [promoters]
have used a monistic theory with a one-shot therapy, and the panacea is the medicine
advertised” (Young 170). Testimonials such as, “I did not call the doctor, but used your
medicine” (Peruna, 1899), showed readers they could save themselves the trouble o f
visiting a physician. The duality o f the language sign systems reinforced this premise as
the authoritative, “scientific” voice in the ads talked about symptoms in vague terms like the “bearing down feeling” (Pinkham, 1879) that all women were reportedly
suffering from - and collaborated with the everyday conversational voice o f eager users
of the drugs.
Without question, the building tasks o f identity, connections, and sign systems and
knowledge that we observed in patent DTCA converged within the discourse to depict a
patent drug maker (who) focusing all o f its energy and advertising space to concentrate
on a product it was selling to the public (what). In fact, the patent drug makers did not
typically claim to be doing otherwise, and this study found no evidence that the patent
DTCA ever included much material o f a truly educational nature. Thus, the entire
situated meaning o f the marketing was to sell a medication and keep consumers from
going to the patent drug makers’ biggest competitor - regular doctors who would most
likely dissuade patients from taking the advertised drugs.
Once this study had clarified the situated meaning o f “what came before” (Gee 114)
the current prescription DTCA, we could now apply the same criteria, or coverage, to
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today’s drug advertising to identity where, if at all, convergence might take place. In the
same building tasks o f identity, connections, and sign systems and knowledge, our
analysis found that almost every point already mentioned for patent DTCA is to some
extent evident in and compatible with the current prescription drug advertising.
Prescription DTCA’s visual component, for example, is used in much the same way
as it was in patent DTCA to build identity and make claims through non-language sign
systems, but this study shows it has more potential to capture attention due to advances in
print media and a change in approach to the public. As we saw in previous examples, the
images still take up at least half o f the advertising space but are now published in glossy,
color photographs that feature people who appear to be healthy. The accompanying
captions, however, simultaneously gam er authority for the pharmaceutical company in
the discourse and make a statement about who should be taking the drag. Unlike patent
DTCA, prescription DTCA tends to spotlight people who are not yet taking the drag and
address readers directly - making frequent use o f “I” statements - to draw the public into
making a connection between their own health and that o f the person in the photograph.
Thus, the current advertising has a more personal effect on its audience than the patent
DTCA once did.
In doing so, the pharmaceutical companies assert their authoritative position by
telling readers that the people in the photographs don’t know how sick they really are.
Ads for Lipitor have emphasized this expert role even further by insisting on including
Dr. Robert Jarvik in every ad as its official, credible spokesperson and superimposing his
image against a laboratory-like setting in the background to make a statement about the
trustworthiness o f the drug. This use o f a personal spokesperson goes back to patent
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DTCA and works because “the perfect testim onial.. .must have the appearance o f truth
and must he acceptable to those who, from lack o f special knowledge, are unable to
recognize any fallacy that may be present” (Holbrook 231).
The versatility o f prescription DTCA’s non-language sign systems when moving
between the building tasks shows convergence in its efforts to keep the readers’ focus on
the advertised drug. This premise is especially evident in the formatting o f the ads. The
ads for Nexium, for example, usually display a prominent graphic o f the “little purple
pill” (Nexium, Jul 2006) near the top of the ad to clearly identify the drug consumers
should request from their doctor. In addition, every ad uses the purple and gold
background that acts as a visual reminder o f the pill itself. These non-language sign
systems not only privilege the medication but also help build relevance (connections) in
the readers’ minds for the drug and its brand name. Like the historical patent ads for
Lydia Pinkham’s Vegetable Compound, the current Nexium ads have a proclivity for
randomly scattering lines o f text in a distinctive font to quickly convey a message about
the drug when the lines are combined. Furthermore, the ads for Lipitor employ
formatting - special blue font that corresponds to the Pfizer logo - that connects the drug
to the company in the discourse and serves as a visual brand-name reminder to
consumers.
In fact, prescription DTCA probably has a greater ability to build identity with
consumers than did the patent DTCA since pharmaceutical companies now have a special
avenue through reminder ads. As we discussed in chapter 2, the FDA’s alignment o f ads
into three separate categories - reminder, help-seeking, and product-claim - has had the
side effect o f allowing pharmaceutical companies to get their brand names out into the
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public to assume a role and make connections without having to worry about discussing
the health effects or risks o f any particular drug. The reminder ads are espeeially adept in
building identity for a company and making connections since the ads, by law, eannot
mention the conditions for which a drug is advertised. This requirement allows the
pharmaceutical companies to foeus entirely on building a positive image as a
manufacturer.
The visual elements definitely aehieve several goals in the situated meaning of
advertising, but the textual component —in the same way it did for patent DTCA ultimately brings together all o f the building tasks o f identity, connections, and sign
systems and knowledge to direct our interest to a drug. In addition to the “I” statements
already mentioned in the discussion o f imagery, the prescription DTCA uses language to
simultaneously show affinity with physicians yet retain authority over the medicine
discussion. The dilemma for today’s pharmaceutieal companies is that - unlike patent
drug makers who eould separate themselves from regular physicians to avoid competition
- they must send consumers to doetors in order to sell the product. Since physicians must
be involved in the process to prescribe the advertised drug, the pharmaceutieal companies
must maintain rapport with the medical field. However, the language o f the prescription
DTCA is often authoritative even when referring to doctors. The ads for Lipitor, for
example, consistently tell readers what doctors “should” be doing to effectively provide
healthcare to patients. As one Lipitor ad remarks, “Your doctor should do blood tests to
check your liver function before and during treatm ent...” (Lipitor, Dee 2007).
The textual elements also work in much the same way as patent DTCA once did to
both make and break conneetions in the discourse. For instanee, the syllogistic
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construction o f the discourse assists in the “medicalization” (Amey & Rafalovich 50) o f
common symptoms, thus enabling consumers to see a condition as being abnormal and
needing a remedy - motifs we first saw in patent DTCA. Today, for example, we even
see ads for Botox that establish the idea for consumers that wrinkles around a woman’s
mouth or eyes signify an undesirable health condition that needs to be fixed.
Furthermore, prescription DTCA also relies on the frequent use o f modal words, like
“could” or “may,” in the discourse to force a connection to certain conditions while
deflecting hlame for any misdiagnosis that m ight occur.
Finally, the text in prescription DTCA often makes irrelevant other forms o f care,
such as diet and exercise or generic, less expensive drugs that would he just as effective.
Interestingly, a recent class-action lawsuit was formed against the makers o f the
prescription drugs Zetia and Vytorin for this method o f breaking connections. The ads
for Zetia and Vytorin have claimed for the last several years that their drugs were more
effective than generic brands, but studies have shown this claim to be false. Ironically for
Lipitor, one o f the ads analyzed in this thesis, the ads for Vytorin are notorious for their
comparisons o f Vytorin to Lipitor in their assertions that Vytorin “lower[s] bad
cholesterol more than Lipitor alone” (Vytorin, Dec 2007). At one time, this comparison
might have demonstrated how well Pfizer, the maker o f Lipitor, was accomplishing its
manufacturing goal since a competitor was using Pfizer’s drug as a benchmark, hut now
the legal action against the makers o f Vytorin, and its advertising comparison, begs the
question about Lipitor’s effectiveness. As a result, the scrutiny o f Lipitor as “one o f the
most researched medicines” (Lipitor, Dec 2007) is sure to continue. In fact. Congress
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recently expressed iriterest in questioning Lipitor’s spokesperson, Dr. Robert Jarvik,
about misleading statements and practices in the DTCA (Saul).
The connections which are broken or established in prescription DTCA are further
reinforced by and compatible with the sign systems o f multiple social languages.
Prescription DTCA, for example, mirrors the patent DTCA in its use o f both authoritative
and conversational social languages. Most o f the ads we examined for Nexium and
Lipitor exhibited the tendency to first diagnose a condition from stated symptoms and
then prescribe a remedy - the advertised drug. In doing so, the ads included language
that spoke to consumers as a friend or peer would. These two sign systems work well
together, just as they did in patent DTCA, to build trust and highlight the advertised drug.
FDA regulations, however, have influenced a third language in prescription DTCA that
creates a fundamental problem for advertisers.
The text on the reverse side o f product-claim ads in many ways negates the efforts o f
the social languages on the traditional marketing side o f the ads. From a continuity
standpoint, the risks and contraindications listed on the back o f the ads do not converge
well with the building tasks previously discussed. On the surface, this lack of
convergence with what came before in the discourse might appear to indicate that the
pharmaceutical companies are correct in their assertions that they are interacting in a
different situated meaning, but in fact, the pharmaceutical companies have this third
language thrust upon them. Read closely, the FDA-mandated text actually works against
the pharmaceutical companies’ claims that they are educating consumers about diseases
or conditions.

98

The tone on the front side o f the ads, for instance, helps build the companies’ identity
with its direct, conversational address to readers, but the reverse side o f the ads abruptly
breaks the cormection with prescriptive language in a third-person, judicial voice. The
material does little to educate a consumer about illnesses because this part o f the
advertising is only required to contain usage information about the advertised drug, and
pharmaceutical companies do not usually add any other information that is not mandated.
Interestingly, Harvard Business School also found that the listing o f negative side effects
o f a drug, especially in the DTCA for Lipitor, actually decreased patients’ compliance
with a prescription drug regimen (Wosinska). Furthermore, consumers often do not take
the time to read through the complex wording. Instead, patients remember a few key
phrases they might gather from the front side o f the ads and depend on physicians to
know all the benefits and risks o f every prescription drug on the market.
As a result, product-claim DTCA has essentially de-privileged the interaction that
doctors used to have only with drug companies, and consumers are now invited into a
three-way conversation they may not be adequately prepared to have. Before the FDA
allowed DTCA, pharmaceutical companies could only advertise to physicians, so doctors
were better able to monitor claims about medications. Now, however, consumers are
seeing many advertisements before their physicians do, and regardless o f the multiple
forms o f sign systems in any drug ad, the patient ultimately seeks wording that promises
relief from an adverse condition. Doctors claim patients now come to them, motivated by
the DTCA, with only a surface knowledge o f a drug. This situation has caused many
critics o f DTCA to lobby for changes in the learned intermediary doctrine - the legal
framework that releases pharmaceutical companies from liability because courts ruled (in

99

the 1960’s) that doctors were in the best position to warn patients o f all medication
dangers. The opponents o f DTCA state the learned intermediary doctrine should be
changed to place more responsibility on the shoulders o f the pharmaceutical companies
since the advertising bypasses the physician’s control (Ronald).
As it stands now, the superficial awareness o f a drug and the connections established
to symptoms o f a medical condition in DTCA’s situated meaning make some patients
feel they can enter into the medical discourse on equal terms with the other participants.
Pharmaceutical companies may create their ads with the ideal audience in mind,
intending to reach only people who understand they must rely on a physician’s training
for medical advice, but doctors are seeing patients who feel they now have the requisite
knowledge to debate the necessity o f a medicine. Unfortunately, mass marketing
prescription medications is not the same as marketing other commercial products. The
ideal audience on a general population level does not exist because every medical
condition varies slightly from another. Thus, the risk o f a patient’s misinterpretation of
an ad or a medical illness is a very real factor.
O f course, pharmaceutical companies claim they subvert this danger by including the
advice to see a doctor; however, the drug manufacturers cannot accurately claim that the
ads’ persistent encouragement to “see your doctor” is altruistic on their part. Once again,
these statements are FDA-mandated text that actually help the drug makers allay some
responsibility - under the learned intermediary doctrine - for genuinely educating
consumers. Even if the FDA did not require the wording, this tactic might not be as
effective as pharmaceutical companies might hope. First, relying on doctors to dissuade
the patient from taking a non-indicated medicine means that physicians must use valuable
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time getting familiar with every new drug on the market and talking patients out of
certain choices. Fearful o f losing patients who might feel a doctor visit was not
satisfactory (i.e. the doctor did not prescribe the requested drug), many physicians admit
they sometimes prescribe a medication simply because the patient wanted it, as long as
the drug would not harm the patient (Murray et al, 515). Second, most patients again do
not have the training necessary to understand the complex interplay o f symptoms and
often are not able to distinguish their health issues from those indicated in the ads.
Therefore, upon careful analysis that included G ee’s validity criteria of both coverage
and convergence, this thesis has determined that, for all o f its advances in technology and
FDA control, prescription DTCA has not moved very far - at least not significantly from the situated meaning o f patent DTCA. The pharmaceutical companies’ claims that
they are using the DTCA to educate the consumers might be true to the extent that they
are informing the readers about a drug on the market. But, the claim that they are
providing education about diseases and conditions is not well supported in the analysis o f
their discourse. In fact, many o f the elements o f the ads make it difficult to find
significant information about the causes o f or preventative measures for health conditions
and diseases. Rather the entire focus o f prescription DTCA, as it was for patent DTCA,
is promotion o f the advertised drug and mitigation o f competition.
In today’s society, there is nothing wrong with advertising medications as a
marketing tool; however, if pharmaceutical companies want to show they are sincere in
their efforts to educate consumers about diseases or conditions, they must demonstrate
this desire in the DTCA. A recommendation this study would make to them would be to
structure the discourse in a way that equally privileges information about medical
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illnesses and treatments versus spending so much time on a particular drug. As we saw,
pharmaceutical companies today already have a very effective way to capture readers’
attention as they build identity through reminder and help-seeking ads, so they could
easily use that momentum to make information about lifestyle choices and alternative
care more relevant in the images and text. In addition, the reverse side o f product claim
ads, while it must contain side effects and risks o f a drug, could easily be transformed
through a better balance o f discussion for both drug and illness while using a social
language which is more easily accessible to the audience.
While pharmaceutical companies might aspire to educate in DTCA, they are
ultimately in business to make a profit. Therefore, consumers must look critically at
prescription DTCA to determine the best course o f action to take for their health
concerns. As Dr. Marcia Angell, editor o f the New England Journal o f Medicine
asserted, “ ...th at’s not their [pharmaceutical companies] business, education. Drug
companies are not in the education business. Medical schools and teaching hospitals are.
It’s like expecting beer companies to educate people about alcoholism. It is not what
they do.” So, even with FDA controls in place and further studies in progress,
pharmaceutical advertising has the potential to be misleading, or at the very least
confusing, for readers. Furthermore, through the comparison in this study, we can see
that today’s prescription DTCA has not significantly distanced its imagery and text - and
consequently its situated meaning —from the who doing what o f patent DTCA (see
Figure 17).
As consumers, we should remember that as early as the Renaissance, Galen said there
were three factors which could do much to build a patient’s confidence in physic: “a
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strong personality in whom the individual has faith;” “an environment rieh in symbols;”
and “ suggestion” in a eourse o f treatment (qtd in Harley 431), so we must be eautious
when reading ourselves into the discourse o f pharmaceutical advertising. As
demonstrated in this thesis. G ee’s building tasks o f identity, conneetions, and sign
systems and knowledge can help illustrate the methods drug companies use to establish
an image with the public, make certain information relevant or not, and manipulate the
sign systems o f medical discourse to influence patients’ decisions to request a drug from
their doctors. Patient education through advertising, as espoused by pharmaceutical
companies, eould be beneficial for patient and doctor alike, but true knowledge should be
an end result.
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